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Abstract 
 
Breast cancer is the most common cancer in the UK and approximately 1 in 8 women 
will be affected by the disease.  Estrogen regulates breast cancer growth through the 
action of the estrogen receptors ERα and ERβ.  Antiestrogens, in particular tamoxifen, 
have contributed greatly to the reduction in breast cancer mortality.  Tamoxifen is a 
tissue selective antiestrogen; it is antiestrogenic in the breast but estrogenic in other 
tissues, thereby enabling it to promote the beneficial effects of estrogen, such as 
maintaining bone density.  However, like estrogen, tamoxifen also promotes 
endometrial cancer, so there is an impetus for the development of novel tissue 
selective ERα ligands.  
 
Regulation of gene expression by the estrogen receptors requires the ligand-regulated 
recruitment of transcription coregulator proteins.  In breast cancer ERα-coactivator 
interactions are associated with tumour progression while ERα-corepressor 
interactions are associated with receptor antagonism and a therapeutic block of ERα 
signalling.   
 
This thesis details the development of a luciferase fragment complementation assay to 
image the interaction of ERα with the coactivator AIB1 and corepressor SMRT.  It is 
hoped that elucidation of these interactions will enable a greater appreciation of the 
tissue selective actions of ERα ligands and aid in the screening of novel ERα 
antagonists.   
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By means of complimentary luciferase fragment fusion proteins, it is shown that 
ligand dependent ERα-coregulator interaction can be imaged in vitro and in vivo.  
ERα and AIB1 luciferase fusion proteins indicate an E2 induced increase in luciferase 
fragment complementation which is modulated by antiestrogens. The 
complementation observed correlates with ERα transcriptional activity and the 
specificity has been further validated by ERα fusion protein mutants.  Consistent with 
the notion that the ERα-SMRT interaction is characteristic of ERα antagonism, ERα 
and SMRT fusion proteins show increased luciferase fragment complementation with 
antiestrogens compared with estrogen. 
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1.1  Breast cancer 
 
Breast cancer is the most common cancer in the UK and it is estimated that 1 in 8 
women will be affected by the disease during their lifetime (CRUK, 2011a).  
Globally, breast cancer is the most common cause of female cancer death (Ferlay J, 
2010).  Breast cancer incidence is the highest in developed western countries and the 
incidence increases as countries become more developed.  An individual’s risk of 
breast cancer increases if they move from a low-risk to a high-risk country (Ziegler et 
al., 1993).  This indicates that lifestyle plays an important role in the development of 
breast cancer. Identified factors associated with increased breast cancer incidence 
include an early menarche or late menopause, having few or no children, having 
children later in life, not breastfeeding, and the use of exogenous hormones such as 
the contraceptive pill or hormone replace therapy (HRT), as well as diet related 
increases, including alcohol consumption and obesity (CRUK, 2011b).  The incidence 
of breast cancer has steadily increased in the UK over the last 30 years: 75 women per 
100,000 were diagnosed with the disease in 1979, which increased to 124 women per 
100,000 in 2008 (CRUK, 2011a, Hery et al., 2008).  Although incidence has 
increased, patient survival rates have also greatly improved: the 5 year survival rate 
for women diagnosed between 1971 and 1975 was 52%, but for women diagnosed 
between 2001 and 2006 the 5 year survival rate was 82%.  The breast cancer 
screening program and improved treatment options are thought to be responsible for 
the trend towards increased survival among breast cancer patients (CRUK, 2011c, 
Ferlay J, 2010) 
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1.2  Estrogen 
 
Estrogens are steroid sex hormones that promote cellular proliferation and survival.   
They are required for the development and maintenance of normal sexual and 
reproductive function, in addition to performing a range of more homeostatic 
functions in the cardiovascular, musculoskeletal, immune and central nervous systems 
(Huang and Kaley, 2004, Riggs et al., 2002, Heldring et al., 2007).  In females, there 
are 3 major types of estrogen, estrone, estradiol and estriol, which are all synthesised 
from androgens by the aromatase enzyme.  17β-estradiol (E2) is the dominant 
estrogen from menarche to menopause; estrone and estriol are associated with the 
menopause and pregnancy, respectively. 
 
Removal of the ovaries has been recognised as being an effective treatment for breast 
cancer since 1896, however, it was not appreciated that this was due to the production 
of estrogen by the ovaries for another 40 years (Jensen and Jordan, 2003).  The link 
between estrogen exposure and breast cancer risk has been extensively demonstrated 
by epidemiological studies and is supported by in vitro and in vivo preclinical work 
which shows estrogen is capable of transforming breast epithelial cells and increases 
the incidence and growth of breast cancer in rodents (Clemons and Goss, 2001, 
Henderson and Feigelson, 2000, Henderson et al., 1982, Jensen and Jordan, 2003, 
Russo et al., 2006). 
 
1.3  Estrogen receptors 
 
Estrogens signal through the estrogen receptor (ER), of which there are two types, 
ERα and ERβ (Enmark and Gustafsson, 1999).  Both ERs are members of the nuclear 
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hormone receptor superfamily, which includes receptors for other steroidal and non-
steroidal hormones such as progestins, glucocorticoids, thyroid hormones, retinoids, 
androgens and vitamin D, as well as various orphan receptors which have no known 
ligand (Mangelsdorf et al., 1995). 
 
The ERs proteins share the conserved structure common to the majority of nuclear 
receptors (Figure 1.1).  They have two regions required for transcription activation, 
activation functions AF1 and AF2; AF1 is contained within the amino terminal A/B 
region and can act in a ligand-independent manner when isolated from the ligand 
binding domain (LBD), while AF2 is located in the carboxy terminal E/F region and 
is intrinsic to the LBD (Tora et al., 1989b, Lees et al., 1989).  Estrogens and 
antiestrogens bind to the LBD, located in region E. DNA binding is mediated by a 
near central DNA binding domain (DBD; region C), consisting of two zinc finger 
motifs.  A “hinge” region (region D) is involved in nuclear localisation and interaction 
with heat shock protein complexes (Kumar et al., 1987).  The DBD is highly 
conserved between ERα and ERβ, and the receptors bind to the same consensus 
deoxyribonucleic acid (DNA) sequences with similar affinities (Enmark et al., 1997). 
ERα and ERβ also bind to E2, and the antiestrogens 4-hydroxytamoxifen (OHT) and 
ICI 182, 780 (ICI) with similar affinities.  However, selective synthetic ligands for 
ERα and ERβ have been identified.  In reporter gene assays, ERα and ERβ show 
differential transcription activation with the differences in activity likely to be due for 
the greater part to the low amino acid sequence homology between the two receptors 
(Kuiper et al., 1997). 
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1 184 264 302 553 595
A/B C D E F
AF-1 DBD LBD AF2
ERα:
Function:
ERα/ERβ identity: 18% 97% 30% 59% 18%  
 
Figure 1.1 - Structure of human ERα. Cloning of ERα from different species highlighted regions of 
differing amino acid sequence homologies across the length of the protein, resulting in the naming of 
regions A-F (Krust et al 1986). Subsequent deletional analysis linked these regions with specific 
activities. ERα shares the conserved nuclear receptor structure consisting of an amino terminal ligand 
independent activation function  (AF1; A/B), a DNA binding domain (DBD; C), a hinge region (D) and 
a ligand dependent activation function (AF2; E/F), which incorporates the ligand binding domain 
(LBD).  The numbers show the amino acid position that represents the start and end of the different 
domains. Amino acid sequence identity in the different domains for human ERα and ERβ is also shown 
(Enmark et al., 1997). 
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ERα and ERβ are believed to have distinct and non-redundant roles, and this is 
supported by their differing expression patterns and ligand specificities (Mosselman et 
al., 1996, Pearce and Jordan, 2004, Kuiper et al., 1997).  Indeed, it has been reported 
that at some promoters ERα and ERβ are capable of producing opposing responses 
(Liu et al., 2002).  Although ERβ is expressed in normal and malignant breast tissue, 
current evidence suggests that it is principally ERα, rather than ERβ, that is 
responsible for the estrogen associated pathology of breast cancer, and will be the 
focus of the remainder of this report (Hartman et al., 2009, Anderson, 2002).   
 
1.4 Estrogen signalling 
ERα is a transcription factor whose activity is regulated by phosphorylation, 
methylation, acetylation, sumoylation and ubiquitination (Le Romancer et al., 2011).  
In the classical ligand dependent signalling pathway, ligand binding to the ER 
stimulates a conformational change in the receptor that results in heat-shock protein 
dissociation and receptor homodimerisation, or heterodimerisation with ERβ (Kumar 
and Chambon, 1988, Pace et al., 1997).  Depending on the specific post-translational 
modifications induced by the ligand, the receptor is then able to alter the transcription 
of the cell.  The most widely studied post-translational modification of ERα is 
phosphorylation, which enables ERα to influence cellular transcription in a ligand-
dependent and ligand-independent manner (Chen et al., 2002).  Phosphoylation of 
ERα, particularly at serines -104, -106, -118 and -167, is associated with 
transcriptional activation of the receptor (Ali et al., 1993, Chen et al., 2002, Thomas et 
al., 2008).  Ligand independent ERα phosphorylation and signalling is associated with 
activation of intracellular signalling cascades, such as the mitogen activated protein 
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kinase (MAPK) pathway which is particularly associated with growth factor 
signalling (Cenni and Picard, 1999, El-Tanani and Green, 1997, Chen et al., 2002).  
 
1.4.1  Genomic signalling 
 
Once activated, ERα is able to affect cellular transcription in a number of different 
ways (Figure 1.2).  The canonical mechanisms through which estrogen regulates gene 
expression is through ER binding as a dimer to a 13 base pair (bp) palindromic 
estrogen response element (ERE), first identified in the Xenopus vitellogenin A2 gene 
and having the consensus sequence GGTCANNNTGACC, where N represents any 
nucleotide (Klein-Hitpass et al., 1986).  However, ERα is also able to regulate the 
expression of genes which do not contain an ERE by interaction with other 
transcription factors, particularly activator protein 1 (AP-1) and specificity protein 1 
(Sp-1) (Saville et al., 2000, Kushner et al., 2000).  Indeed, chromatin 
immunoprecipitation (ChIP) in U2OS cells has suggested that as few as 11% of E2 
regulated genes contain an ERE (Levy et al., 2008).  
 
1.4.2  Non genomic signalling 
 
In addition to nuclear ER, accumulating evidence suggests the existence of a plasma 
membrane ER, which mediates changes in intracellular signalling within a few 
minutes of estrogen addition; too rapid to be attributed to transcription dependent ER 
actions.  Membrane initiated ER signalling results in activation of the MAPK/ERK 
and phosphoinositide 3-kinase (PI3K)/AKT pathways, which is thought to occur, at 
least in part, through activation of insulin-like growth factor receptor I (IGF-IR), 
epidermal growth factor receptor (EGFR) and human epidermal growth factor 
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receptor 2 (HER2) (Song et al., 2006, Song et al., 2007, Song et al., 2002, Razandi et 
al., 2003, Shou et al., 2004).  As this aspect is not a feature of the work reported in the 
thesis, I will not describe these activities any further, although it is noteworthy that 
activation of intracellular kinases could affect the genomic actions of ERα through 
phosphorylation of ERα and its cofactors (Font de Mora and Brown, 2000, Shou et 
al., 2004).   
 
1.4.3  Transcription Regulation by ERα 
 
Chromatin bound ERα is able to stimulate or block the transcription of estrogen 
responsive genes by recruitment of coactivator or corepressor proteins, which is 
thought to be primarily determined by the specific receptor conformation induced by 
ligand binding.  Crystallographic studies of the ER-LBD have revealed that agonist 
and antagonist ligands produce distinct receptor conformations which promote or 
occlude coactivator binding.  The ER-LBD is a wedge shaped structure composed of 
antiparallel α-helices; in the agonist bound receptor, the carboxy helix 12 folds over 
the ligand binding cavity to reveal a hydrophobic groove which is the interaction 
surface for coactivator proteins.  When bound by antagonists such as tamoxifen or 
raloxifene, helix 12 is displaced and the hydrophobic groove is not formed, thereby 
preventing coactivator interaction (Shiau et al., 1998, Brzozowski et al., 1997).   
 
ERα-mediated transcription activation has been shown to be associated with the 
recruitment of a range of coactivator proteins such as the DRIP/TRAP (vitamin D 
receptor interacting protein/thyroid hormone receptor associated proteins) complex, 
p300, CBP (cyclic adenosine monophosphate (cAMP) response element binding 
(CREB) binding protein), pCAF (p300/CBP associated factor) and steroid receptor 
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coactivators (SRC) -1, -2, and -3.  These proteins primarily interact with the ER-LBD 
through the conserved coactivator nuclear receptor recognition sequence: LXXLL, 
where L is leucine and X is any amino acid (Torchia et al., 1997, Heery et al., 1997).  
However, non-LXXLL coactivator-ERα AF1 interactions have also been reported 
which are believed to be required for AF1 activity and synergism with the AF2 (Webb 
et al., 1998).  Coactivator proteins are able to promote transcription by modifying the 
chromatin structure and acting as a scaffold for the recruitment of additional proteins 
as part of transcritption complex assembly.  In particular, a number of coactivator 
proteins have been shown to possess intrinsic histone acetyltransferase (HAT) 
activity; histone acetylation has been shown to be associated with increased gene 
transcription (Glass and Rosenfeld, 2000).  ChIP experiments have shown that the 
recruitment of ERα, coactivators and ribonucleic acid (RNA) polymerase II to 
estrogen responsive promoters occurs in a dynamic process with cycles of association 
and disassociation which last approximately 60 minutes (Shang et al., 2000).   
 
1.4.3.1  AIB1 
 
Amplified in breast cancer 1 (AIB1, also referred to as SRC3 and NCoA3) is a 
member of the p160 family of nuclear receptor transcriptional coactivators, which 
also includes SRC1 (NCoA1) and SRC2 (TIF2, GRIP1, NCoA2).  The p160 family of 
coactivators are able to bind to nuclear receptors, including ERα, and recruit 
additional coactivator proteins and components of the transcriptional machinery to the 
promoter.  In addition to their functioning as adaptors between nuclear receptors and 
other coactivator proteins, SRC1 and AIB1 also possess intrinsic HAT activity  
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Figure 1.2 - ER signalling. The ER can stimulate transcription from promoters containing an estrogen 
response element (ERE) or through tethering to other transcription factors (TF), such as AP-1 and Sp-1 
regulated gene promoters.  Estrogen signalling can be stimulated in a ligand dependent and ligand 
independent manner by estrogen (E2) and growth factor signalling, respectively.  E2 binding to the ER 
also stimulates rapid non-genomic membrane initiated ER signalling, which is associated with the 
activation of the AKT and ERK1/2 signalling pathways.  ER antagonists, such as 4-hydroxytamoxifen 
(OHT), can repress ER transcriptional activity from ERE and AP1 or SP1 site containing promoters by 
promoting corepressor (CoR) rather than coactivator (CoA) recruitment.  Figure adapted from  (Le 
Romancer et al., 2011) 
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and can modify the chromatin directly (Wu et al., 2005, Klinge, 2000, Chen et al., 
1997, Spencer et al., 1997). 
 
AIB1 was originally identified from screening of breast cancer cell lines to identify 
genes associated with regions of amplification in breast cancer cell lines.  Several 
studies have subsequently investigated AIB1 amplification and expression in normal 
and malignant tissues.  Although there inconsistencies regarding the degree of 
amplification and overexpression in tumour samples, increased AIB1 does appear to 
be associated with a malignant phenotype; amplification of the AIB1 gene has been 
reported in 2-10% of breast tumours and over-expression has been reported in as 
many as 64% of breast tumours (Anzick et al., 1997, Bouras et al., 2001, Kirkegaard 
et al., 2007, Murphy et al., 2000, Iwase et al., 2003).  A causal role for high AIB1 
expression in breast cancer is supported by the high incidence of mammary tumours 
in transgenic mice which over-express AIB1 (Torres-Arzayus et al., 2004).  In vitro 
analysis indicates that AIB1 is a critical factor in ERα signalling: AIB1 interacts with 
ERα in an E2 dependent manner and can stimulate a dose dependent increase in ERα 
signalling.  Depletion of endogenous AIB1 has shown that it is a rate limiting factor 
for ERα transcription and estrogen dependent growth (Anzick et al., 1997, Li et al., 
1997, List et al., 2001, Shang and Brown, 2002).  In vitro analyses have also shown 
that the activity and stability of AIB1 is regulated by a ‘phosphorylation code’; 
different combinations of the 9 identified phosphorylation sites spread across AIB1 
are phosphorylated in response to different stimuli, and the precise residues 
phosphorylated determine the transcription factors to which AIB1 is recruited and 
AIB1 turn-over (Wu et al., 2007, Wu et al., 2004, Gojis et al., 2010). 
 
  29
Clinically, high expression of AIB1 in breast tumours is associated with a poor 
response to tamoxifen, particularly in HER2 over-expressing tumours (Osborne et al., 
2003).  Laboratory studies have suggested that this could be a consequence of 
increased birdirectional cross-talk between the ER and EGFR/HER2 pathways in 
these cells; in breast cancer cells which express high levels of AIB1 and HER2 it has 
been shown that OHT acts as an agonist in an EGFR/HER2 dependent manner.  The 
critical interaction between ER/AIB1 and the EGFR/HER2 pathways in tamoxifen 
resistance is further supported by an in vivo model which indicates that the acquisition 
of tamoxifen resistance is associated with increased EGFR and HER2 expression and 
signalling.  A recent study has indicated that combining OHT treatment with an 
EGFR inhibitor may be beneficial for some patients (Osborne et al., 2011, Schiff et 
al., 2003, Massarweh et al., 2008).   
 
1.4.3.2  Transcription repression by ERα  
 
In contrast to ER agonists, ER antagonists induce a receptor conformation which 
promotes the recruitment of corepressor proteins.  The nuclear receptor corepressor 
(NCoR) and silencing mediator of retinoic acid and thyroid hormone receptors 
(SMRT) proteins were originally identified by their ability to interact with unliganded 
nuclear receptors (Horlein et al., 1995, Chen and Evans, 1995).  The structurally 
similar proteins have since been shown to interact with steroid hormone receptors, 
including ERα, to mediate the repressive effects of receptor antagonists (Lavinsky et 
al., 1998, Zhang et al., 1998, Chen et al., 1996, Ordentlich et al., 1999).  Corepressors 
interact with the hormone binding domain of ERα and other nuclear receptors through 
conserved CoRNR (‘corner’) boxes within the carboxy terminus of the proteins.  The 
CoRNR boxes have the amino acid sequence (I/L)XX(I/V)I , where X is any amino 
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acid (Hu and Lazar, 1999, Nagy et al., 1999, Webb et al., 2000).  Both corepressor 
proteins function as a bridge between nuclear receptors and proteins with histone 
deacetlyase (HDAC) activity.  Histone deacetylation results in a more condensed 
chromatin structure and has been shown to be associated with gene repression (Hu 
and Lazar, 1999, Klinge, 2000).  In addition to being regulated by changes in the 
nuclear receptor, NCoR and SMRT interactions are also affected by phosphorylation 
of the corepressors.  However, although NCoR and SMRT appear to be structurally 
and functionally very similar, the proteins are phosphorylated in response to different 
cellular signalling pathways (Jonas and Privalsky, 2004, Privalsky, 2004, Hermanson 
et al., 2002, Jepsen and Rosenfeld, 2002).  Phosphorylation of NCoR and SMRT can 
enhance or inhibit binding to nuclear receptors. 
 
Both NCoR and SMRT interact with ERα in the presence of the antiestrogens OHT 
and raloxifene.  The importance of NCoR and SMRT in determining the 
agonist/antagonist actions of OHT are supported by experiments showing that 
silencing of the corepressors can ablate the growth repressive effects of OHT and 
overexpression of SMRT can reduce some of the agonist actions of OHT (Keeton and 
Brown, 2005, Shang and Brown, 2002, Smith et al., 1997, Lavinsky et al., 1998). 
 
1.5  Estrogen signalling as a therapeutic target 
 
Approximately two thirds of all breast tumours express ERα and the growth of 50-
70% of these can be arrested by inhibiting estrogen signalling (Clark et al., 1984).  An 
interruption of estrogen signalling has been achieved through various methods, 
including blocking estrogen binding to its receptor, down regulating the receptor and 
inhibiting the synthesis of estrogen.  However, because of the range of effects which 
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estrogen exerts in tissues other than the breast and uterus, a complete withdrawal of 
estrogen can be associated with a range of negative side effects, most notably 
menopausal symptoms, joint problems and a loss of bone density (Lintermans et al., 
2011, Scott et al., 2011).   
 
1.5.1  SERMs 
 
Selective estrogen receptor modulators (SERMs) are compounds that are able to 
agonise or antagonise estrogen signalling in different contexts. Their mixed 
agonist/antagonist actions offer the potential to block the negative effects of estrogen 
in the breast and uterus while maintaining its positive influence in the bones and 
cardiovascular system.    
 
Tamoxifen, one of the first clinically applicable SERMs, has been used to 
successfully treat breast cancer for over 20 years (Lewis and Jordan, 2005).  
Approximately half of all ERα+ breast cancer patients respond favourably to 
tamoxifen, and when used as an adjuvant, tamoxifen almost halves the annual 
likelihood of disease recurrence and prolongs a patient’s overall disease free survival 
(EBCTCG, 1992, EBCTCG, 1998, Osborne, 1998).  In high-risk patients, tamoxifen 
has also been used as a chemopreventive agent and can reduce breast cancer incidence 
by up to 50% (Fisher et al., 1998, Cuzick et al., 2003).  Tamoxifen is particularly 
attractive as a breast cancer therapy because, in addition to blocking estrogen action in 
the breast, its use increases bone mineral density and reduces cholesterol; as such, 
tamoxifen use is associated with a reduction in osteoporotic fractures and 
cardiovascular deaths (Costantino et al., 1997, Fisher et al., 2005, Kristensen et al., 
1994, Rutqvist and Mattsson, 1993, Love et al., 1992).  However, although tamoxifen 
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blocks the negative actions of estrogen in the breast and promotes estrogenic action to 
maintain bone density, it is not the ideal SERM; long term tamoxifen use is associated 
with an increased risk of endometrial cancer because it acts as a partial agonist in the 
uterus (Lewis and Jordan, 2005, Jordan et al., 1987, Turner et al., 1987, Love et al., 
1992, Shang and Brown, 2002, Fisher et al., 1994, Fornander et al., 1989).  
Tamoxifen use is also associated with other negative side effects such as hot flushes.  
Raloxifene is a SERM used for the prevention and treatment of osteoporosis which 
has been identified as being associated with a reduced risk of breast cancer.  In the 
Study of Tamoxifen and Raloxifene (STAR) trial, tamoxifen and raloxifene were 
compared for breast cancer prevention, and it was shown that both drugs provide 
bone-protective and lipid-lowering effects but the increased incidence of endometrial 
cancer observed with tamoxifen was reduced with raloxifene.  However, raloxifene 
was also less effective than tamoxifen at reducing the incidence of breast cancer 
(Vogel et al., 2006).  Because of these limitations, there continues to be much interest 
in the development of novel SERMs and antiestrogens for the treatment of breast 
cancer and other estrogen associated diseases such as osteoporosis (Papoutsi et al., 
2007, Yadav et al., 2011).   
 
1.5.1.1  SERM mode of action 
 
The mechanism through which SERMs are able to exert E2 agonist and antagonist 
properties in different contexts is not fully understood, although it has been shown 
that it depends on the N terminal AF1 region of ERα and is promoter and cell context 
specific (Katzenellenbogen et al., 2000, Berry et al., 1990, Tzukerman et al., 1994).  
The transcriptional activity of ERα at different gene promoters is determined by the 
recruitment of coactivator or corepressor proteins, which was classically thought to 
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depend upon the specific receptor conformation induced by different ligands.  
However, this clearly does not account for the actions of SERMs, where a single 
ligand can act as an ERα agonist and antagonist in different cell types.  For example, 
OHT is an ERα antagonist in breast cancer cells but a mild agonist in endometrial 
cells; the agonist and antagonist actions of OHT in breast and endometrial cell has 
been shown to correlate with the recruitment of coactivator and corepressor proteins, 
respectively (Shang and Brown, 2002).  The ability of OHT bound ERα to recruit 
different coregulators in different contexts is attributed to tissue specific epigenetic 
factors such as the relative and absolute expression levels of ERα and its coregulators, 
tissue specific post-translational modifications of proteins, including ERα and its 
coregulators, and the promoter context (Osborne et al., 2003, Shang and Brown, 2002, 
Green and Carroll, 2007, Wu et al., 2005).  The pivotal role that coactivator and 
corepressor proteins play in the tissue specific actions of SERMs has been 
demonstrated with knock-down and overexpression studies.  In one study it was 
shown that the agonist actions of OHT in endometrial cell lines is dependent on 
relatively high expression levels of SRC1: knock down of SRC1 in endometrial cells 
ablates OHT stimulated gene expression and overexpression of SRC1 in breast cancer 
cells results in OHT stimulated gene expression similar to that seen in endometrial 
cells (Shang and Brown, 2002).  Similarly, knock-down of nuclear receptor 
corepressors can enhance the agonist actions of OHT (Smith et al., 1997, Lavinsky et 
al., 1998, Keeton and Brown, 2005).  It has also been proposed that changes in 
coregulator expression levels could, at least in part, be responsible for the 
development of endocrine resistance (Schiff et al., 2003).   
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Nuclear receptors are attractive drug targets for a range of different disease states and 
the central role that coactivator and corepressor interactions play in determining 
nuclear receptor activity has led several groups to develop methods to measure 
nuclear receptor-coregulator interactions (Llopis et al., 2000, Zhou et al., 1998, 
Jankevics et al., 2005, Sladek, 2003, Iannone et al., 2004, Bai and Giguere, 2003, 
Awais et al., 2007, Hultman et al., 2005, Stafslien et al., 2007). 
 
1.6  Molecular imaging  
Molecular imaging has been defined as “the visualization, characterization, and 
measurement of biological processes at molecular and cellular levels in humans and 
other living systems” (Mankoff, 2007).  This has been achieved through numerous 
strategies, including labelled antibodies and receptor ligands, activated enzyme 
substrates and transcriptional reporters.  Clinically, molecular imaging enables a 
greater depth of understanding than anatomical imaging alone, and is of particular use 
for the personalisation of medical treatments. 
 
Within the field of cancer biology there are numerous applications of molecular 
imaging; molecular imaging can be used to identify tumours and distant metastases 
and can also be used to characterize the tumour to determine the best treatment 
strategy.  Similarly, a focus on the intracellular processes rather than external 
morphology allows molecular imaging to identify the response to treatment sooner 
than a reduction in tumour size could be observed (Kelloff et al., 2005).  Preclinically, 
molecular imaging in small animal models is used extensively in assessing the value 
of pharmaceutical targets and the efficacy of compounds which target them. 
  35
Positron emission tomography (PET) is perhaps the most widely used molecular 
imaging modality in clinical oncology.  [18F]fluorodeoxyglucose (FDG), a glucose 
analogue, can be used as a marker of tumour growth to diagnose, stage and investigate 
treatment response.  PET has many advantages as an imaging technique; it allows 
good resolution, quantitative 3D imaging of superficial and deep tissues in clinical 
and preclinical applications (Table 1.1).  However, PET imaging is also very 
expensive, relatively slow and requires the use of radioactive isotopes.  Magnetic 
resonance imaging (MRI) and ultrasound imaging are other clinically applicable 
imaging techniques, which both produce high resolution images, however their 
strengths currently lie in anatomical imaging with limited molecular imaging probes 
and applications.   
 
1.7  Bioluminescence imaging 
Bioluminescence imaging (BLI) is an optical imaging technique that can be used for 
in vitro and in vivo visualization of biological processes.  It relies upon modification 
of cells or organisms to express a luciferase enzyme, which produces light as a by-
product of substrate catalysis.  The requirement for luciferase expression prohibits its 
use in humans, however, as a preclinical tool it has many advantages.   
 
BLI in small animals is conducted using a cooled charge coupled device (CCD) 
camera.  Mice are injected with the enzyme substrate intraperitoneally, anaesthetised, 
and then placed in a light tight imaging chamber with a CCD camera above (Figure 
1.3).  Two images  
   
3
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Table 1.1 - Comparison of molecular imaging modalities. Adapted from (Massoud and Gambhir, 2003) 
 
 PET MRI Ultrasound Fluorescence BLI 
Contrast agent Radiolabelled probe None or paramagnetic contrast agent 
None or microbubble 
contrast agent 
Fluorophore tagged 
probe 
Genetically modified to 
express luciferase 
enzyme 
Sensitivity +++ + ++ ++ +++ 
Spatial resolution 1-2mm 25-100µm 50-500µm 3-5mm* 3-5mm* 
Temporal resolution ++ + +++ +++ +++ 
Clinical application      
Cost £££ £££ £ £ £ 
Quantitative +++ ++ + ++ ++ 
Throughput + + ++ +++ +++ 
Deep imaging +++ +++ ++ + + 
 
 
 
* Depth dependent, decreases as a function of signal origin depth 
PET; positron emission tomography 
MRI; magnetic resonance imaging 
BLI; bioluminescence imaging 
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Figure 1.3 - IVIS imaging system. Mice are anaesthetised in the anaesthetic induction box (A) prior to 
transfer to the 37°C imaging chamber (B).  The sample stage is height adjustable and has an anaesthetic 
manifold for up to 5 subjects.  Photon emission from subjects is captured using the cooled CCD 
camera (C).    
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are acquired; a grey scale photographic image and a bioluminescence image.  The 
acquisition time for the bioluminescence image depends on the signal strength but 
ranges from seconds to minutes.  The photonic signal emitted from the sample is 
captured by the CCD camera and converted into an electrical signal, thereby allowing 
emission from a given area to be quantified.  The quantified bioluminescence signal 
data is then superimposed over the grey scale image using a pseudo-colour intensity 
scale.  Photon emission is proportional to amounts of luciferase protein over several 
orders of magnitude, which enables signal quantification over a broad range.    
 
As a method for small animal imaging, BLI is generally preferred to fluorescence 
imaging.  This is principally because BLI is associated with a very low background 
signal, which makes the technique very sensitive and capable of detecting low 
intensity signals (Troy et al., 2004).  Although fluorescence probes usually emit much 
more light, the requirement for an exogenous light source and tissue autofluorescence 
produce a high background signal, which reduces the sensitivity of the technique and 
limits its potential for in vivo imaging.   
 
Non-invasive BLI can be performed on the same subjects on multiple occasions, 
which enables longitudinal studies with animals acting as their own controls.  Repeat 
imaging can reduce the number of animals required for each experiment and also 
reduce data variability, which can further reduce the number of animals required for 
each experiment.  Repeated fluorescence imaging can be more problematic because of 
fluorophore photobleaching.   
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As an imaging modality, BLI lends itself to high throughput applications.  Using the 
IVIS imaging system, up to 5 mice can be imaged at the same time with acquisition 
times of a few minutes.  The imaging procedure is also relatively low cost; once the 
imaging equipment has been purchased, the only reagents required for scanning are 
the anaesthetic and enzyme substrate, which cost a few pounds per mouse.  
Experimentation costs are also reduced if fewer animals are used for each experiment.   
 
1.7.1  Luciferase 
Bioluminescent light production is dependent on luciferase enzymes.  Luciferases 
have been isolated from many different organisms, including bacteria, insects and a 
range of marine organisms (Hastings, 1996).  All luciferases are oxygenases and 
require oxygen to oxidate their substrate luciferin (S) to form an excited-state product 
(P*) which decays to ground state (P) emitting light (hv).   
S + O2 → P* → P + hv 
Although all luciferases are oxygenases, the diversity of enzyme and substrate 
structure suggests that the ability to emit light evolved more than once (Hastings, 
1983) .   
 
Whilst luciferase genes have been identified in many species, the luciferase enzyme 
from the North American firefly Photinus pyralis is the most widely used for in vivo 
imaging.  Firefly luciferase is a 62 kilodalton (KDa), 550 amino acid protein which 
consists of a large N-terminal domain and a smaller C-terminal domain joined by a 
flexible hinge region (de Wet et al., 1985, de Wet et al., 1987, Conti et al., 1996).  
  40
Firefly luciferase catalyses the conversion of its substrate D-luciferin to oxyluciferin 
using oxygen and adenosine triphosphate (ATP), emitting a broad spectrum of light 
with a peak of approximately 610nm at 37°C (Zhao et al., 2005).  This emission 
spectrum is particularly favourable for in vivo imaging because light absorption by 
tissue elements, particularly haemoglobin and water, is greatest in the blue-green 
spectrum and is less at wavelengths above 600nm (Zhao et al., 2005, Weissleder and 
Ntziachristos, 2003).  In addition to its favourable emission spectrum, firefly 
luciferase is also well suited to in vivo imaging because the signal it emits is relatively 
bright and stable and the substrate D-luciferin has good bioavailability (Bhaumik and 
Gambhir, 2002, Luker and Luker, 2008).   
 
Firefly luciferase has been widely used for imaging biological systems.  The ATP 
dependence of the enzyme has lent itself to use in ATP detection assays, but it has 
also been used to monitor cell fate, gene expression, enzymatic activity and 
messenger RNA (mRNA) stability (Ciana et al., 2003, Neufeld et al., 1975, Caceres et 
al., 2003, Hickson et al., 2010, Laguette et al., 2011).  More recently split-luciferase 
assays have been used to study protein-protein interactions and protein conformations.     
 
1.8  Imaging protein-protein interactions 
 
 
Protein-protein interactions are fundamental to most cellular processes and can 
produce numerous outcomes.  As such, the study of protein-protein interactions is 
important in biological sciences.  As far as reasonably possible, it is desirable to study 
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protein-protein interactions in living cells and in living subjects: with the aim that the 
interactions observed are true representations of the endogenous scenario.   
 
Interaction networks and novel interaction partners can be investigated using 
techniques such as affinity chromatography, affinity blotting and yeast-two hybrid or 
other library based methods.  Using these techniques, the protein of interest in used as 
a bait to identify interacting proteins for further analysis.  These assays can be 
performed to a greater or lesser degree in a native cellular environment, but can be 
associated with a high number of false positives and negatives (von Mering et al., 
2002).   
 
Coimmunoprecipitation (CoIP), a mainstay molecular biology technique, is widely 
used to investigate protein-protein interactions and can be applied to the study of 
interactions between endogenous proteins.  It can be used to identify novel interaction 
partners, verify interacting proteins identified by other methods, and investigate the 
factors which affect the interaction of two or more proteins.  CoIP depends upon 
antibody specificity and can be associated with a relatively high background signal, 
which can limit its use to the investigation of relatively high affinity interactions 
between abundant proteins (Berggard et al., 2007). CoIP also requires individual 
sample preparation for each interaction snapshot and is not readily applicable to 
imaging dynamic interactions or interaction kinetics in an in vivo context.     
 
Fluorescence resonance energy transfer (FRET) is the gold standard for imaging 
interaction dynamics between two proteins of interest.  FRET occurs between two 
fluorophores when the emission spectrum of the donor fluorophore overlaps the 
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excitation spectrum of the acceptor fluorophore; this has been applied to the study of 
protein-protein interactions by tagging interacting proteins with appropriate donor and 
acceptor fluorophores (Fernandez and Berlin, 1976).  The acceptor:donor 
fluorescence ratio increases when proteins are within 100 angstroms (Ǻ) of each 
other, allowing the fluorescence ratio to be used as a molecular ruler (Stryer and 
Haugland, 1967).  The discovery and cloning of genetically encoded fluorescent 
proteins has enabled FRET to be applied to imaging protein-protein interaction 
kinetics in live cells (Prasher et al., 1992, Shimomura et al., 1962, Day et al., 2001, 
Demarco et al., 2006, Llopis et al., 2000, Sun et al., 2011).  However, because of the 
limitations associated with fluorescence imaging in animal models, namely low 
sensitivity, FRET is not well suited to in vivo imaging.  Bioluminescence resonance 
energy transfer (BRET), where a bioluminescent light source is used to excite the 
acceptor fluorophore, which excludes the requirement for an external light source, is 
an adaptation of FRET which offers the potential to investigate protein-protein 
interactions in living subjects.  However, at present the method is still in its infancy 
and suitable donor and acceptor proteins for in vivo imaging are still being developed 
in proof of principle experiments (De and Gambhir, 2005, De et al., 2009, 
Dragulescu-Andrasi et al., 2011). 
 
Perhaps the most effective method for imaging protein-protein interactions in living 
subjects is the split reporter assay, in particular those using luciferases and thymidine 
kinase (Bhaumik and Gambhir, 2002, Massoud et al., 2010, Paulmurugan et al., 
2002).  These split reporter assays are a development of ubiquitin, β-galactosidase and 
dihydrofolate reductase protein fragment complementation assays, which have 
previously been used to image protein-protein interactions (Johnsson and Varshavsky, 
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1994, Pelletier et al., 1998, Rossi et al., 1997, Paulmurugan et al., 2002).  As 
previously discussed, PET imaging (using thymidine kinase split reporter assays) 
provides highly resolved, 3D, deep tissue imaging, but it is relatively expensive, slow 
and dangerous.  Firefly and Renilla luciferases are the predominant luciferases which 
have been used for imaging protein-protein interactions in living subjects.  Because of 
its emission spectrum, substrate bioavailability and robust signal, firefly luciferase is 
the preferred luciferase for imaging in vivo (Zhao et al., 2005).  
 
1.8.1  Luciferase fragment complementation assay 
 
The basis of the luciferase fragment complementation assay is that the enzyme can be 
split into two subunits, the N-terminal and C-terminal luciferase fragments (NLuc and 
CLuc, respectively).  Individually these fragments are absent of activity, but when 
they are brought into close proximity they are able to complement and enzymatic 
activity is restored.  In order to image protein-protein interactions the NLuc and CLuc 
fragments are fused in frame with two interacting proteins of interest; when the 
proteins interact, the luciferase fragments are brought into close proximity and 
complement so the interaction can be imaged by the restoration of luciferase activity 
(Figure 1.4).  The luciferase fragments used should not self-complement, and so in the 
absence of interaction between the two proteins of interest, minimal luciferase activity 
should be observed.  Firefly, Renilla, Gaussia and click beetle luciferases have all 
been used to image protein-protein interactions using such an assay (Villalobos et al., 
2010, Paulmurugan et al., 2004, Luker et al., 2004, Remy and Michnick, 2006).  The 
optimal location to split firefly luciferase for complementation assays has been found 
to be in the region of the flexible hinge between the N- and C-terminal protein 
domains (Luker et al., 2004, Paulmurugan and Gambhir, 2007).  The specific 
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luciferase fragments used and their position within the fusion protein has been shown 
to significantly alter the luciferase activity observed in the presence and absence of 
the interaction inducer; luciferase fragments which spontaneously complement have 
also been identified (Paulmurugan and Gambhir, 2007).   
 
Firefly luciferase protein complementation has been applied to the detection of a 
range of biological processes in vivo, including ligand-induced CXCR4 and EGFR 
activation, AKT activation and apoptosis (Li et al., 2008, Luker et al., 2008, Zhang et 
al., 2007, Coppola et al., 2008).  It has also been successfully employed to detect 
protein-protein interactions in plants (Chen et al., 2008).  More recently, red and 
green click beetle luciferases have been used to image interactions between three 
proteins (Villalobos et al., 2010).   
 
In studying protein-protein interactions, it is desirable to use a method which is 
capable of indicating interaction kinetics.  In cellular systems, different time-course 
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NLuc CLuc
NLuc-Protein A Protein B-CLuc
A
B
 
Figure 1.4 - Luciferase fragment complementation assay. (A) The luciferase enzyme can be split 
into two enzymatically inactive subunits, NLuc and CLuc, which can complement when brought into 
close proximity.  (B) By fusing NLuc and CLuc to Protein-A and Protein-B, the interaction between 
Protein-A and Protein-B can be detected by the emission of light in the presence of the substrate 
luciferin.    
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 studies have indicated that split-luciferase proteins require ligand or interaction-
inducer incubations in the range of minutes to hours in order to reach a plateau in 
luciferase fragment complementation.  It has been argued that the range of different 
incubations required are a reflection of the time frame of the specific processes being 
monitored or membrane permeability to ligand, rather than complementation between 
the luciferase fragments being the rate limiting step; in cell free systems or cell 
lysates, a signal plateau is reached within 1-2 minutes (Luker et al., 2004, Taneoka et 
al., 2009, Luker et al., 2008, Luker et al., 2009, Yang et al., 2009, Villalobos et al., 
2010).   
 
In addition to being able to detect the kinetics of protein-protein interactions, the 
ability to image interaction dynamics is also desirable.  In principle, protein fragment 
complementation assays should be reversible because the restored reporter activity 
only depends on protein folding and not covalent modification of the luciferase 
fragments, although green and yellow fluorescent protein complementation assays 
have been demonstrated to be irreversible (Hu et al., 2002, Magliery et al., 2005).  
However, the available evidence suggests that this is not the case for luciferase 
fragment complementation assays; to date, Gaussia, Renilla and click beetle 
luciferase fragment complementation assay have all been shown to be reversible in 
nature (Villalobos et al., 2010, Stefan et al., 2007, Remy and Michnick, 2006).  
Depending on the system being studied, reduced complementation between luciferase 
fragments was observed in seconds to minutes in these studies.    
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1.9  Imaging ER activity 
 
Given the central role that ERα plays in the development and progression of breast 
cancer and its use as a therapeutic target, various methods to image ER activity have 
been developed by different groups. These broadly fall into two categories; 
transcriptional reporters and ER-coregulator interaction assays.   
 
The central role that ER coactivators and corepressors play in determining the activity 
of ER has been exploited as a mechanism for imaging ER activity.  Using a range of 
fluorescence based techniques, the association of the full length ERα, ERα-LBD or 
ERβ with coactivator LXXLL peptides or the receptor interaction domains (RID) 
have been imaged.  These assays have been used to determine the pharmacology of 
novel ERα ligands and the specific coactivator preferences of ERα and ERβ relative 
to other nuclear receptors (Liu et al., 2003, Zhou et al., 1998, Llopis et al., 2000, Bai 
and Giguere, 2003, Dong et al., 2006, Iannone et al., 2004, Jankevics et al., 2005, 
Weatherman et al., 2002).  Because of the limitations of fluorescence for in vivo 
imaging, these studies have all been conducted with purified proteins or in cultured 
cells. 
 
In vivo and ex vivo imaging of ER activity has been achieved with transcriptional 
reporters.  Transgenic ERE-luciferase reporter mice have been developed to image 
time and tissue dependent ER transcription in response to different ligands (Ciana et 
al., 2001, Ciana et al., 2003, Della Torre et al., 2011, Lemmen et al., 2004).  Using 
these mice, it has been shown that the magnitude and time-frame of ERE activity in 
response E2 is different in different tissues.  ERE-green fluorescent protein (GFP) and 
ERE-β-galactosidase transgenic mice have also been developed for ex vivo analysis of 
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ligand specific ER activation in different tissues (Toda et al., 2004, Nagel et al., 
2001).  In order to specifically appreciate transcriptional activation mediated by ERα, 
rather than the combined actions of ERα and ERβ from the classic ERE, an ERα 
activity indicator model mouse has recently been developed.  A bacterial artificial 
chromosome has been used to achieve endogenous expression levels of an ERα 
protein in which the DBD has been replaced with the Gal4 DBD.  This enables ERα 
specific expression of GFP in different tissues in response to ligand, although to date 
this reporter has only been used in proof-of-principle experiments (Han et al., 2009). 
 
1.10  Thesis synopsis 
 
The aim of this project was to develop a luciferase fragment complementation assay 
that would allow non-invasive in vivo imaging of the interactions between ERα and 
key transcriptional coregulator proteins.  It was hoped that the development of such a 
method would allow imaging of the tissue-selective activities of agonist and 
antagonist bound ERα.  As the split-luciferase method provides the most sensitive 
method for in vivo imaging of protein-protein interactions (see above), I decided to 
generate constructs based on the split-luciferase constructs described by Professor S 
Gambhir (Paulmurugan and Gambhir, 2007).  AIB1 and SMRT were chosen as an 
ERα coactivator and a corepressor, respectively, as these proteins are known to have 
important roles in regulation of agonist and antagonist bound ERα activities. To 
perform such studies in vivo, I first generated a series of ERα-coregulator split-
luciferase constructs and characterised their activities in vitro before imaging selected 
constructs in vivo.  The results of these studies are presented, and the value of such an 
approach for imaging ERα-coregulator interactions in vivo and as a means of 
developing an understanding of the tissue-specific action of ERα agonists and 
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antagonists are discussed, together with a discussion of possible future direction.
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Chapter 2 Materials and Methods 
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2.1  Chemicals, enzymes and reagents 
 
Unless otherwise stated, all chemicals and reagents were obtained from Sigma 
Aldrich (Gillingham, UK).  BamHI, NheI, XhoI and KpnI restriction enzymes, 
deoxyribonucleotide triphosphates (dNTPs), high fidelity PCR enzyme mix, 
FastAP™ thermosensitive alkaline phosphatase, T4 DNA ligase, and protein and 
DNA size markers for electrophoresis were all purchased from Fermentas Life 
Sciences (St Leon-Rot, Germany). 
 
2.2  Plasmids 
 
pcDNA-NLuc-FKBP12-rapamycin binding protein (FRB) and pcDNA-FK506 
binding protein 1A (FKBP12)-CLuc were a gift from Professor S. Gambhir at 
Stanford University.  The coding sequences for ERα, AIB1 and SMRT were obtained 
from the plasmids pSG5-HEG0 (Tora et al., 1989a), (Tora et al., 1989a), pcDNA-
AIB1 (Anzick et al., 1997) and pCMX-SMRT (Chen and Evans, 1995), respectively.  
Renilla luciferase was from the pRLTK vector (Promega, Southampton, UK).   
 
2.3  Polymerase chain reaction (PCR) 
 
Sequences for cloning were amplified by PCR.  Each reaction contained 0.5ng DNA 
template, 1µM of each primer, 200nM dNTP and 2.5U of high fidelity enzyme mix in 
1 x high fidelity PCR buffer.  PCR was performed for 35 cycles of 94°C for 1 minute, 
60°C for 1 minute and 72°C for 3 minutes, with a final elongation step at 72°C for 10 
minutes.  PCR products were column purified using the QIAquick PCR Purification 
Kit (Qiagen, Crawley, UK) immediately after the PCR in order to avoid degradation 
of the amplified product.   
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2.4  Agarose gel electrophoresis 
 
Nucleic acids were separated by 0.5-1.5% agarose gel electrophoresis in 1 x TBE 
buffer (90mM tris(hydroxymethyl)aminomethane (tris), 90mM boric acid, 20mM 
ethylendiaminetetraaceticacid (EDTA)).  Incorporated into the gel for nucleic acid 
staining was either 0.003% ethidium bromide or 1 x SYBR® Nucleic Acid Gel Stain 
(Invitrogen, Paisley, UK). 
 
2.5  DNA ligations and bacterial transformation 
 
25ng ligations were performed with a 1:1 and 3:1 molar ratio of insert:vector with 5 
enzyme units (U) T4 DNA ligase in 1 x ligase buffer overnight at room temperature. 
50µl of DH5α Escherichia coli (E.coli; Invitrogen) were transformed with 10ng of 
ligation product by placing on ice for 30 minutes prior to heat shock at 42°C for 30 
seconds followed by 2 minutes on ice.  The bacteria were then allowed to recover by 
the addition of 1ml Super Optimal Broth (SOB; Invitrogen) and incubation at 37°C 
for 1 hour before plating on Luria broth (LB)-agar plates, containing 100µg/ml 
ampicillin.  Plates were incubated at 37°C overnight.  Individual colonies from the 
plates were expanded in 3ml of LB overnight and plasmid DNA was prepared from 
the cultures using the GeneJET™ Plasmid Miniprep Kit (Fermentas). Plasmid DNAs 
were screened for the presence of an insert by restriction enzyme digestion and 
confirmed by sequencing.   
 
2.6  Construction of luciferase-fragment reporter plasmids 
 
The ERα, AIB1 and SMRT split-luciferase reporter constructs were generated through 
modification of pcDNA-NLuc-FRB (pcDNA-Nhe1-Firefly luciferase amino acids 1-
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398 – BamHI – FRB – XhoI) and pcDNA-FKBP12-CLuc (pcDNA-Nhe1- FKBP12– 
BamH1 – Firefly luciferase 394-550 – XhoI).    
 
To prepare the backbones, FRB and FKBP12 were excised; pcDNA-NLuc-FRB was 
digested with BamHI and XhoI in 1 x BamHI buffer using a 2-fold excess of XhoI    
and pcDNA-FKBP12-CLuc was digested with NheI and XhoI in 1 x Tango buffer 
(Fermentas).  Digests were performed at 37°C for 2 hours.  The enzymes were heat 
inactivated at 65°C for 15 minutes prior to agarose gel electrophoresis of the digest 
products. Fragments of the appropriate size (approximately 6.5 and 5.9 kilo-base pair 
(Kb) for pcDNA-NLuc and pcDNA-CLuc respectively) were excised and purified 
from the gels using the QIAquick Gel Extraction Kit (Qiagen).  Because FRB and 
FKBP12 are both relatively small (approximately 300bp each), the excised fragments 
may be contaminated with linearised vectors, resulting from incomplete restriction 
enzyme digestion.  So, to prevent re-ligation of partially digested vectors, 5’ 
phosphates were removed using a thermosensitive alkaline phosphatase for 10 
minutes at 37°C.  The alkaline phosphatase was heat inactivated at 75°C for 15 
minutes prior to ligation reactions. 
 
To replace FRB and FKBP12, full length or “interaction domains” of ERα, AIB1 and 
SMRT were PCR amplified for cloning into the pcDNA-NLuc or pcDNA-CLuc 
backbones.  The primers used for the PCR reactions had restriction enzyme sites 
engineered into them and transcription start/stop codons inserted/removed as 
appropriate (Table 2.1).  Prior to ligation, the column purified PCR products were 
digested and gel purified as described for the backbones. 
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Ligations between pcDNA-NLuc and pcDNA-CLuc and the inserts were performed 
and the constructs sequenced for verification.  25ng ligations were performed with a 
1:1 and 1:3 molar ratio of vector to insert in 10µl volume.  Reactions were incubated 
overnight at room temperature.   
 
To generate the G4S flexible spacer, oligonucleotides having the sequences 5’-
GATCCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGTACCC-3’ and 5’-
GATCGGGTACCGCTGCCACCTCCGCCTGAACCGCCTCCACCG-3’ were 
heated in a 1:1 molar ratio in annealing buffer (10mM tris, 50mM NaCl, 1nM EDTA, 
pH 8.0) to 80°C in a water bath for 10 minutes, then allowed to cool slowly overnight.  
To insert, plasmids were digested between the luciferase-fragment and fusion protein 
with BamHI, gel purified and then ligated with the insert.  Insertion of the spacer 
introduced a KpnI restriction enzyme site, which was used to screen for positives. The 
number of spacers inserted and their orientation was determined by sequencing. 
 
Mutant ERα constructs were generated using the QuickChange Site-Directed 
Mutagenesis kit (Agilent Technologies, Edinburgh, UK).  The primers used were 5’- 
TGGTGCCCCTCTATGACGCGGCGCTGGAGATGCTGGACG-3’, 5’ 
CGTCCAGCATCTCCAGCGCCGCGTCATAGAGGGGCACCA-3’ for the 
L539A/L540A mutants and 5’-AAGAACGTGGTGCCCCTCTCTGACCTGCTG-3’ 
and 5’-CAGCAGGTCAGAGAGGGGCACCACGTTCTT-3’ for the Y537S mutants. 
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Table 2.1 - Oligonucleotides used for construction of split-luciferase constructs. Primer sequences 
which complement the template (and are used for primer annealing) are shown in capital letters.  Lower 
case denotes sequences not present in the gene of interest. Restriction enzyme sites are in bold. “-“ in 
the primer sequence denotes a deleted base relative to the gene sequence. 
 
 
Split-luciferase 
construct 
(pcDNA-) 
PCR product 
(Protein: 
 amino acids) 
Primer sequence (5'-3') 
 
NLuc-ER ERα:  F - agatcggatccACCCTCCACACCAAAGCATCTGGG 
 4-595 R - tgatcctcgagTCAGACTGTGGCAGGGAAACCCTCTGCC 
NLuc-ER-LBD ERα: F - agatcggatccTCTGCTGGAGACATGAGAGCTGCC 
 282-595 R - tgatcctcgagTCAGACTGTGGCAGGGAAACCCTCTGCC 
ER-CLuc ERα:  F - agatcgctagcATGACCATGACCCTCCACACCAAAGC 
 1-595 R - tgatcggaTCCGACTGTGGCAGGGAAACCCTCTGCCTCCCCCGT  
ER-LBD-CLuc ERα:  F - agatcgctagcatGTCTGCTGGAGACATGAGAGCTGCC 
 282-595 R - tgatcggaTCCGACTGTGGCAGGGAAACCCTCTGCCTCCCCCGT 
NLuc-AIB1 AIB1:  F -agatcGGATCC-CTGGCCAGTGATTCACGAAAAC 
 11-1424 R - tgatcctcgagtcaGCAGTATTTCTGATCAGGACC 
NLuc-AIB-RID AIB1:  F - agatcggatccGTGGAGAGTTCAATGTGTCAGTC 
 580-839 R - cagacctcgagctaCAAACCCAGAGAATTAGTTCCTT 
AIB1-CLuc AIB1: F - agatcgctagcaTGGCCAGTGATTCACGAAAACGCAAATTGCC 
 12-1424 R - tgatcggatccGCAGTATTTCTGATCAGGACCCATAGG 
AIB-RID-CLuc AIB1: F - agatcgctagcatgGTGGAGAGTTCAATGTGTCAGTC 
 580-839 R - tgatcggatccCAAACCCAGAGAATTAGTTCCTTG 
NLuc-SMRT-RID SMRT: F - agatcggatccACCCCTGCGAAGAACCTCGCAC  
 1988-2462 R - tgatcctcgagTCACTCGCTGTCGGAGAG 
SMRT-RID-CLuc SMRT:  F - agatcgctagccatgACCCCTGCGAAGAACCTCGCACCTC 
 1988-2462 R - tgatcggatccCTCGCTGTCGGAGAG  
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2.7  Cell lines and culturing 
All cell culture reagents were obtained from Invitrogen unless otherwise stated.  293H 
(human embryonic kidney; Invitrogen), Ishikawa (endometrial adenocarcinoma; 
Sigma-Aldrich), U2OS (osteosarcoma; ATCC, Teddington, UK), MCF7 (breast 
adenocarcinoma; ATCC) and MELN (MCF7-ERE- Luciferase; (Balaguer et al., 
2001)) cells were all routinely maintained at 37°C in a 5% CO2 atmosphere, in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2mM L-
glutamine, 10% foetal calf serum (FCS; Lonza, Slough, UK), 100U/ml penicillin, 
100ug/ml streptomycin and 1ug/ml Fungizone™ antimycotic.   
 
Prior to estrogen induction experiments, cells were grown for a minimum of 3 days in 
phenol red-free DMEM supplemented with 2mM L-glutamine and 5% double 
charcoal and T70 dextran-coated charcoal-stripped FCS (Interlink UK, Birmingham, 
UK) and were maintained in the charcoal-stripped medium for the duration of the 
assay.  E2, OHT, raloxifene hydrochloride and ICI 182,780 (Tocris Bioscience, 
Bristol, UK) were solubilised in ethanol.  Rapamycin (Merck, Hoddesdon, UK) was 
solubilised in dimethyl sulfoxide (DMSO). 
 
2.8  Preparation of cell lysates 
 
Whole cell lysates were prepared using radioimmunoprecipitation assay (RIPA) 
buffer (50mM Tris-HCl pH7.2, 150mM NaCl, 1% NP40, 1% sodium deoxycholate, 
0.1% sodium dodecyl sulphate (SDS)) with 1 x protease inhibitor cocktail (final 
concentration 1mM 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride 
(AEBSF.HCl), 800nM aprotinin, 50µM bestatin, 15µM E-64, 5µM EDTA, 20µM 
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leupeptin, 10µM pepstatin A; Thermo Scientific, Loughborough, UK).  Culture 
medium was poured or aspirated from the tissue culture vessel and cells were washed 
twice in ice-cold phosphate buffered saline (PBS) on ice.  Lysis buffer was added to 
the cells and a cell scrapper was used to detach and collect the cells.  The cells were 
then transferred to a tube, agitated by vortexing, and kept on ice for 30 minutes with 3 
additional vortexes at 10 minute intervals.  Cell debris was then cleared from the 
lysates by centrifugation at 16,000xg for 10 minutes at 4°C and the supernatant was 
transferred to a new tube and stored at -80°C.  Protein concentration was determined 
using a bicinchoninic acid (BCA) protein assay (Thermo Scientific). 
 
 
2.9  Cell growth assays 
 
A sulforhodamine B (SRB) assay was used to assay cell growth and cytotoxicity in 96 
well plates.  Cells were fixed for 1 hour at 4°C after addition of 50µl of ice-cold 50% 
tricholoacetic acid (TCA) onto 200µl growth medium.  Plates were then thoroughly 
rinsed under a running tap and plates were dried.  Adhered cell were stained with 
0.4% SRB in 1% acetic acid for 30 minutes, after which unincorporated dye was 
removed by rinsing in 1% acetic acid.  After drying, bound dye was solubilised by 
adding 200µl of 10mM Tris to wells and absorbance was measured at 565nm.   
 
2.10  Cell transfection 
 
Details specified are based upon transfection in a 96 well plate format, quantities were 
scaled up for transfections in 6 well and 10cm plates (33- and 200-fold respectively).  
One day prior to transfection, cells were plated at 70-80% confluency in antibiotic-
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free media.  The following day, the cells in each well were transfected with 200ng 
plasmid and 0.6µl Lipofectamine 2000 transfection reagent (Invitrogen) using DMEM 
supplemented with 2mM L-glutamine.  For luciferase assays, 50ng of pRLTK was 
transfected with the experimental plasmids in order to normalize data with regard to 
transfection efficiency.  6 hours post-transfection, the transfection mixture was 
removed and replaced with fresh media, containing estrogen, antiestrogens or 
rapamycin, as appropriate.  An equal volume of the solvent was added to vehicle 
controls. 
 
For stable cell line generation, Lipofectamine LTX transfection reagent (Invitrogen) 
was used according to the manufacturer’s instructions.  Cells were seeded to 80% 
confluency in 6 well plates and transfected the following day using 5µg plasmid 
DNA.  To increase yield a range of transfection conditions were routinely used; 
reactions were performed using 10µl and 20µl of Lipofectamine LTX with 2.5µl or 
7.5µl of Plus Reagent.  After 6 hours, media were changed.  The following day, cells 
were passaged into 15cm tissue culture plates and selective antibiotics, 4µg/ml 
puromycin and 500µg/ml G418 as appropriate, were added the following day to select 
for stable integrants. SRB assays had been carried out to determine the lowest 
concentration of these antibiotics at which all cells die in the absence of transfection 
with the plasmids encoding the resistance genes. Selective antibiotic containing media 
was replenished every 4-5 days until colonies formed, usually 2-3 weeks.  Colonies 
were picked using 3mm cloning discs, propagated and screened for luciferase activity 
+/- E2. 
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2.11  Luciferase assays 
 
In vitro luciferase assays were performed in clear-bottom black 96 well plates 
(Corning Incorporated, Amsterdam, The Netherlands).   Luciferase activity was 
quantified using a Topcount:NXT luminescence counter (PerkinElmer, 
Buckinghamshire, UK) or IVIS 100 (Caliper Life Sciences, Runcorn, UK). 
 
For transiently transfected cells, firefly and Renilla luciferase activity was quantified 
using the Dual Glo® Luciferase Assay System (Promega) approximately 48 hours 
post transfection.  Medium was poured/tapped from the wells and 60µl of 1:1 phenol 
red-free DMEM:Luciferase Reagent was added to the wells 10 minutes before 
determination of firefly luciferase activity.  30µl of Stop and Glo reagent was 
subsequently added to the wells and Renilla luciferase activity was obtained 10 
minutes later.  Firefly luciferase readings were normalised to the Renilla luciferase 
transfection efficiency control.   
 
For stably transfected cell lines, luciferase activity was measured in live cells 
approximately 48 hours after treatment by the addition of 200µg/ml D-luciferin 
potassium salt in PBS (Gold Biotechnology, Missouri, USA).  Where stipulated, the 
luciferase activity measured was normalised to total protein; after quantification of 
luciferase activity, cells were washed twice in PBS and 25µl of RIPA buffer was 
added to wells before freezing at -80°C.  Plates were subsequently defrosted for 1 
hour at room temperature with shaking and the protein content was determined using 
a BCA protein assay (Thermo Scientific). 
 
  60
2.12  In vivo imaging 
 
All animals were housed in individually ventilated cages (IVC) within the CBS 
facilities at Imperial College.  Procedures and humane end points were defined and 
adhered to according to the project license and Home Office regulations. 
 
Prior to implantation, cells were washed twice in PBS, counted with a 
haemocytometer and resuspended in PBS.  100µl of cell suspension containing 1-
10x106 cells was injected subcutaneously into the flank or scruff of 4-6 week old 
female nu/nu BALB/c mice (Harlan, Bicester, UK) anaesthetised with isoflurane 
(Abbot Laboratories, Maidenhead, UK).   
 
Where tumours were allowed to develop, the volume was calculated from tumour 
caliper measurements using the ellipsoid volume formula π/6 x (tumour length(mm) x 
tumour width(mm) x tumour breadth(mm)) (Tomayko and Reynolds, 1989)  
 
Estrogen and tamoxifen were administered to mice through slow release pellets; 
0.72mg/60 day 17β-estadiol, 5mg/60 day tamoxifen or 60 day placebo pellets 
(Innovative Research of America, Florida, USA) were implanted into isoflurane 
anaesthetized mice either simultaneous to cell injection or 5 days prior.  A small 
incision was made approximately 1.5cm from the desired pellet location and a 
subcutaneous pocket was formed by carefully separating the skin from the muscle 
layer.  The pellet was placed 1.5cm into the pocket (to prevent expulsion) and the skin 
either side of the incision was joined with the absorbable suture Vicryl (Ethicon, 
Edinburgh, UK).  1.64µg/ml Metacam® (Boehringer Bracknell, UK) was added to 
drinking water for 48 hours following surgery as additional pain relief.  Mice were 
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treated with 5mg of ICI 182,780 by subcutaneous administration of 100µl of the 
breast cancer approved drug Faslodex (AstraZeneca, London, UK).  Peanut oil was 
administered as a placebo for fulvestrant. 
 
All in vivo imaging was conducted using the IVIS 100 (Caliper Life Sciences).  Mice 
were injected intraperitoneally with 150mg/kg D-luciferin potassium salt (Gold 
Biotechnology)/100µl sterile PBS.  Approximately 10 minutes later, mice were 
aneasthetised with isoflurane and placed into the imaging chamber.  Images were 
acquired using a CCD camera until a signal plateau was reached.  Photon emission 
was quantified using the Living Image Software (Caliper Life Sciences); regions of 
interest (ROI) of a standard area were placed over cell populations and the total 
photons/second (flux) were quantified and used for data analysis after subtraction of 
background ROI values.   
 
For analysis, tumours were excised after sacrifice of the animals, washed in PBS and 
fixed in 4% formaldehyde.  Tissues were embedded, sectioned and stained with 
haematoxylin and eosin (H&E) by the Hammersmith Hospital Histopathology 
department. 
 
2.13  Antibodies 
 
Mouse anti-AIB1 (BD611105) and mouse anti-SMRT (BD611387) were purchased 
from Becton Dickinson and Company (Oxford, UK).  Rabbit anti-AIB1 (sc9119), 
rabbit anti-SMRT (sc20778), mouse anti-ERα (sc8002), rabbit anti-ERα (sc543), 
mouse anti-firefly luciferase (sc57603) and rabbit anti-firefly luciferase (sc32896) 
were purchased from Santa Cruz Biotechnology (Heidelberg, Germany).  Mouse anti-
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β-actin was purchased from Abcam (ab6276; Cambridge, UK).  Goat anti-rabbit 
immunoglobulins (Ig)/horse radish peroxidase (HRP; P0448) and goat anti-mouse 
Ig/HRP (P0447) were purchased from Dako (Ely, UK).  Alexa Fluor® 594 goat anti-
rabbit IgG (A11012), Alexa Fluor® 594 goat anti-mouse IgG (A11005), Alexa 
Fluor® 488 goat anti-rabbit IgG (A11008), Alexa Fluor® 488 goat anti-mouse IgG 
(A11001), rabbit IgG isotype control (10500C) and mouse IgG isotype control 
(10400C) antibodies were purchased from Invitrogen.   
 
2.14  Immunoblotting 
 
2 x loading buffer (125nM tris, 4% SDS, 0.2% bromophenol blue, 200mM 
dithiothreitol (DTT), 20% glycerol, pH6.8) was added to an equal volume of protein 
lysates and the samples were boiled for 5 minutes and resolved by SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE).  1.5mm thick 8x10cm mini-gels 
were cast using the Mighty Small 4-gel Caster (GE Healthcare, Little Chalfort, UK).  
Gels were cast with a 5% stacking gel (5% acrylamide (Protogel, National 
Diagnostics, East Riding, UK), 125mM Tris, 0.1% SDS, pH6.8) and 8% or 10% 
resolving gel (8 or 10% acrylamide, 375mM Tris, 0.1% SDS, pH8.8).  The stacking 
and resolving gels were polymerised with 1:100 10% ammonium persulfate (APS) 
and 1:1000 tetramethylenthylenediamine (TEMED).  Electrophoresis was performed 
in an SE250 Electrophoresis Unit (Hoefer Incorporated, Fisher Scientific, 
Loughborough, UK) with a 25mM Tris, 190mM glycine, 0.1% SDS, pH8.3 running 
buffer.   
 
Following separation by electrophoresis, proteins were transferred to Hybond™ ECL 
nitrocellulose membrane (GE Healthcare) in a 20% methanol, 25mM Tris, 38mM 
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glycine, pH8.3 buffer using the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad, Hemel Hempstead, UK).  Membranes were blocked for 1 hour in blocking buffer 
(5% milk powder, 0.1% Tween 20-PBS (PBS-T)) before incubation with primary 
antibody diluted in blocking buffer overnight at 4°C.  For AIB1 detection, rabbit anti-
AIB1 antibody was diluted 1:4000.  For ERα blotting, mouse anti-ERα antibody was 
diluted 1:1000.  As a loading control, all membranes were blotted for β-actin with a 
mouse anti-β-actin antibody diluted 1:100,000.  Membranes were washed 3 times in 
PBS-T prior to incubation with secondary antibody (goat anti-mouse/rabbit Ig/HRP) 
diluted 1:2000 in blocking buffer for 1 hour at room temperature.  Membranes were 
finally washed 3 more times in PBS-T, incubated with SuperSignal West Pico or 
Femto Chemiluminescent Substrate (Thermo Scientific) and used to exposure of 
Amersham Hyperfilm ECL (GE Healthcare). 
 
2.15  Immunofluorescence 
 
Cells were plated in chamber slides (Corning Incorporated) prior to transfection 
and/or treatment.  24 hours after plating or treatment, cells were washed twice in ice-
cold PBS and fixed with 4% formaldehyde for 15 minutes at 37°C.  Cells were 
subsequently washed 3 times in PBS, permeabilised with 0.1% Triton-X-PBS (PBS-
Tx) for 10 minutes and then blocked with 1% bovine serum albumin (BSA)-PBS-Tx 
for 1 hour.  Cells were incubated with primary antibodies diluted 1:150 in 1%BSA-
PBS-Tx for 1 hour.  Primary antibody was removed with 3 washes in PBS-Tx before 
incubation with secondary antibodies diluted 1:400 in 1%BSA-PBS-Tx for 1 hour at 
room temperature.  Cells were finally washed 3 times in PBS-Tx and mounted with 
Prolong® Gold antifade with DAPI (4’,6-diamidino-2-phenylindole; Invitrogen). 
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2.16  Statistical analysis 
 
All statistical analysis was performed using Prism 5.01 (Graphpad Software, 
California, USA).  An unpaired t-test was used to compare results +/- treatment and 
an analysis of variance (ANOVA) was used to compare larger data sets.  Bonferroni  
or Dunnett’s multiple comparison post tests were used to compare all results or results 
relative to vehicle, respectively. 
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Chapter 3 Results 
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3.1  Characterisation of MELN cell line 
 
The capacity to image estrogen receptor activity is an important tool for the 
development of novel estrogen receptor modulators.  The MELN cell line is an ERα 
transcriptional reporter.  It is an MCF7 cell line which has been stably transfected 
with an estrogen responsive promoter driving transcription of the firefly luciferase 
reporter gene (ERE-Luciferase, (Balaguer et al., 2001)).  I chose to use the MELN cell 
line as a control for the split luciferase constructs developed during this project.  For 
this reason, an initial characterization of the cell line was performed. 
 
Incubation of the MELN cell line with E2 produced a dose dependent increase in 
luciferase activity (Figure 3.1A).  Peak luciferase activity was observed at 
concentrations of 10-8M, although near maximal activity was obtained at a 
concentration of 10-11M E2.  The luciferase activity observed with E2 was greater 
with longer E2 incubations (Figure 3.1B), with luciferase activity being near maximal 
at 8 hours. The antiestrogens OHT (Figure 3.2A) and ICI (Figure 3.2B) inhibited 
luciferase activity observed with 10-9M E2.  With both antiestrogens, partial inhibition 
was observed in the presence of 10-8M antiestrogen and near complete inhibition was 
observed at 10-7M and above.  The luciferase activity observed with higher 
concentrations of the antiestrogens was well below that observed with vehicle 
treatment.  
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Figure 3.1 - E2 response of MELN cells. 1.5x104 MELN cells were treated with vehicle (ethanol) or 
increasing concentrations of E2 for 48 hours (A) or 10-6M E2 for increasing periods of time (B) prior to 
quantification of luciferase activity.  Mean luciferase activities (n = 3) are shown, normalized to total 
protein. Error bars represent the standard errors of the mean (SEM).  The ANOVA test was used to 
determine statistical significance relative to vehicle treatment (***, p ≤ 0.001). 
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Figure 3.2 - Modulation of MELN E2 response by OHT and ICI. 1.5x104 MELN cells were treated 
with vehicle (ethanol) or 10-9M E2 and different concentrations of OHT (A) or ICI (B) for 48 hours.  
Mean luciferase activities (n = 3) are shown, normalized to total protein. Error bars represent the 
standard errors of the mean (SEM).  The ANOVA test was used to determine statistical significance 
relative to the E2 treatment (***, p ≤ 0.001.). 
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In order to assess the tumourgenicity of the MELN cell line and determine if in vivo 
tumour imaging was possible, 1x107 cells were injected subcutaneously into the flank 
of 6 nude mice.  E2 pellets were implanted into the opposing flank at the same time as 
cell inoculation, since MCF7 cells require estrogen for their growth. Tumour 
development was monitored by calliper measurements and by imaging the luciferase 
activity every 7 days (Figure 3.3).  Tumours developed in 4 of the 6 mice inoculated.  
Half of the tumour bearing mice developed palpable tumours within 2 weeks but 
tumour development was much slower in the other 2 mice.  Regardless of tumour 
size, luciferase activity was detectable in all 4 mice at all imaging time points.  
Luciferase activity generally increased as tumour volume increased, although at later 
time points the luciferase activity in the larger tumours decreased even though the 
tumour volume continued to increase; a moderate decrease in luciferase activity was 
observed in mouse #4, but the luciferase activity in mouse #3 showed a significant 
decline so that the activity observed on day 42 was similar to that observed on day 7.  
This reduction in signal could be caused by a necrotic core and reduced blood flow 
(and consequently substrate delivery) in the larger tumours.  Upon sacrifice, H&E 
staining showed that there was significantly more necrosis in the larger tumours of 
mice #3 and #4.  Dissection also revealed that a cyst-like sac had formed around the 
E2 pellet in mouse #3.    
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Figure 3.3 - In vivo bioluminescence imaging of MELN tumours. 1x107 MELN cells were 
subcutaneously injected in to the right flank of mice at the same time as E2 pellet implantation in the 
opposing flank.  Tumour development was monitored for 6 weeks by quantifying luminescence with 
the IVIS 100 (A and C) and by calliper measurements of tumours (B).  (D) Representative H&E 
staining of each tumour is shown. 
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3.2  Characterisation of NLuc-FRB and FKBP12-CLuc 
 
At the start of the project, I was kindly given a pair of split-luciferase vectors by 
Professor Sanjiv Gambhir at Stanford University.  The plasmids encode FK506 
binding protein 1A (FKBP12) and the FKBP12-rapamycin binding (FRB) domain of 
mammalian target of mTOR fused to N- and C-terminal fragments, respectively, of 
firefly luciferase (Figure 3.4).  FKBP12 and FRB exhibit a strong interaction in the 
presence of rapamycin; this interaction should bring the N- and C-terminal portions of 
firefly luciferase into close proximity to allow firefly luciferase reconstitution.  
Hence, the restored firefly luciferase activity allows appreciation and imaging of 
protein-protein interaction.  The aim of my project was to modify the NLuc-
FRB/FKBP12-CLuc split-luciferase to generate an ERα-coregulator interaction assay.   
 
In order to test the FRB-FKBP12 mediated luciferase fragment complementation the 
constructs were transfected into 293 cells individually and together and the cells were 
treated with vehicle or 4x10-7M rapamycin (Figure 3.5). Transfection of the constructs 
individually showed no luciferase activity in the presence of the substrate luciferin, 
consistent with the assertion that the luciferase fragments have no enzymatic activity 
on their own.  When the cells were co-transfected with the two constructs, luciferase 
activity could be detected in the presence and absence of the interaction inducer 
rapamycin.  However, the luciferase activity was stimulated approximately 16-fold in 
the presence of rapamycin.   
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Figure 3.4 - pcDNA-NLuc-FRB and pcDNA-FKBP12-CLuc.  The NLuc fragment is 1194 bp in 
length and encodes amino acids 1-398 of firefly luciferase and is in frame with a 270 bp fragment 
encoding the 90 amino acid FRB, to give the fusion protein NLuc-FRB.  NLuc-FRB is flanked in 
pcDNA-NLuc-FRB by a 5’ Nhe I site and a 3’ Xho I site.  There is a BamHI site between the NLuc and 
FRB coding regions.  The CLuc fragment is 468 bp in length and encodes amino acids 395-550 of 
firefly luciferase.  It is cloned in frame with the 324 bp region encoding the 108 amino acids of 
FKBP12.  The fusion construct is flanked by a 5’ Nhe I site and a 3’ Xho I site and there is a BamHI 
site at the boundary of the FKBP12 and CLuc fragments.  
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Figure 3.5 - FRB-FKBP12 mediated luciferase fragment complementation. 4x104 293H cells were 
transfected with 200ng NLuc-FRB, FKBP12-CLuc or NLuc-FRB and FKBP12-CLuc, as indicated.  
Cells were treated with vehicle (DMSO) or 4x10-7M rapamycin for 24 hours prior to quantification of 
luciferase activity in live cells using the IVIS 100.  (A) Captured image. (B) data quantified from ROI 
measurements showing mean luciferase activities (n = 3).  Error bars represent the standard errors of 
the mean (SEM).  A t-test was used to determine statistical significance relative to vehicle treatment 
(***, p ≤ 0.001).  
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3.3  ERα-coregulator split-luciferase assay feasibility study 
 
Having confirmed that the rapamycin-stimulated interaction of FRB and FKBP12 
allows the functional reconstitution of split firefly luciferase, I wanted to establish 
whether luciferase fragment complementation could be used to assay ERα-coregulator 
interactions.  ERα-coregulator interactions are transient and are therefore likely to be 
considerably weaker than the strong FKBP12-rapamycin-FRB interaction 
(Banaszynski et al., 2005).  
 
I chose to initially focus on the interaction between ERα and the coactivator AIB1.  In 
order to determine whether it was possible to use split-luciferase complementation to 
examine ERα-coactivator interactions, the FKBP12 fragment was excised from 
FKBP12-CLuc and replaced with the ERα ligand binding domain (ER-LBD-CLuc) or 
full-length ERα (ERα-CLuc) coding sequences.  Similarly, the FRB sequences in 
NLuc-FRB were replaced with the AIB1 nuclear receptor interaction domain (NLuc-
AIB-RID), encoded within amino acids 580-839 of human AIB1 (Figure 3.6). As 
previously discussed the ERα-LBD and AIB-RID fragments have previously been 
used to demonstrate nuclear receptor-cofactor interactions in fluorescence-based in 
vitro assays (Bramlett et al., 2001, Chang et al., 1999, Kraichely et al., 2000, Liu et 
al., 2003, Ozers et al., 2005, Zhou et al., 1998).   
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Figure 3.6 - Cloning strategy. (A) FRB and FKBP12 were excised from the appropriate split-
luciferase plasmids by restriction enzyme digestion and the backbones were gel purified.  (B) The AIB-
RID, ER and ER-LBD coding fragments were PCR amplified using primers with appropriate 
restriction enzyme sites engineered into them.  (C) Ligations were performed between the NLuc 
backbone and AIB-RID PCR product and the CLuc backbone and ER and ER-LBD PCR products. 
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At this stage, I did not try to produce a full length AIB1 because I wanted to be sure 
that the assay was capable of detecting transcription factor-coactivator interaction 
before attempting to express the full-length 160 KDa AIB1 as a fusion with NLuc.   
 
To test for functional reconstitution of NLuc and CLuc through the interaction of ERα 
and the AIB1 RID, 293H cells were co-transfected with NLuc-AIB-RID together with 
ER-LBD-CLuc or ER-CLuc, and the cells were treated with 10-6M E2 or vehicle. 
NLuc-FRB/FKBP12-CLuc plasmids +/- rapamycin were also transfected for 
comparison (Figure 3.7). As described above, a 15-fold increase in luciferase 
complementation was observed for NLuc-FRB/FKBP12-CLuc transfected cells 
treated with rapamycin.  Interestingly, cotransfection of NLuc-AIB-RID and ER-
LBD-CLuc yielded luciferase activity that was about 30% of the activity obtained for 
NLuc-FRB/FKBP12-CLuc, suggestive of a strong interaction between the ER-LBD 
and AIB1.  Addition of E2 stimulated the interaction, although there was only a 2-fold 
stimulation.  
 
By contrast, there was very low luciferase activity in the case of the full length ER-
CLuc and NLuc-AIB-RID in the absence of E2.  E2 treatment of the NLuc-AIB-
RID/ER-CLuc transfected cells did produce a small increase in luciferase activity, but 
the signal was very low, less than that observed in vehicle treated NLuc-
FRB/FKBP12-CLuc transfected cells, suggesting poor interaction between full-length 
ERα and the AIB-RID or poor transfection or expression of ER-CLuc.  
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Figure 3.7 - Initial assessment of NLuc-AIB-RID, ER-LBD-CLuc and ER-CLuc. 4x104 293H cells 
were transfected with 200ng NLuc-FRB, FKBP12-CLuc, NLuc-AIB-RID, ER-LBD-CLuc and ER-
CLuc, as indicated.  Cells were treated with vehicle (DMSO), 4x10-7M rapamycin (NLuc-
FRB/FKBP12-CLuc) or 10-6M E2 (NLuc-AIB-RID/ER-LBD-CLuc and NLuc-AIB-RID/ER-CLuc) for 
24 hours prior to quantification of luciferase activity in live cells using the IVIS 100.  (A) Captured 
image (B) data quantified from ROI measurements showing mean luciferase activities (n = 3). Error 
bars represent the standard errors of the mean (SEM).  A t-test was used to determine statistical 
significance (***, p ≤ 0.001, **, p ≤ 0.01).  
 
 
 
 
 
  78
To control for the specificity of the observed increases in luciferase activity for the 
ER and AIB1 fragments, cells were transfected with NLuc-FRB/ER-LBD-CLuc or 
NLuc-AIB-RID/FKBP12-CLuc and treated with rapamycin or E2 (Figure 3.8).  This 
experiment was only performed with NLuc-AIB-RID and ER-LBD-CLuc because of 
the low signal and E2 induction observed with the ER-CLuc constructs. 
 
Treatment of the NLuc-FRB/FKBP12-CLuc transfected cells with rapamycin and 
NLuc-AIB-RID/ER-LBD-CLuc transfected cells with E2 resulted in similar 
stimulation of luciferase activity as before.  As expected, cells co-transfected with 
NLuc-FRB/ER-LBD-CLuc showed very little luciferase activity with vehicle, 
rapamycin or E2 treatment.  However, the cells transfected with NLuc-AIB-
RID/FKBP12-CLuc showed moderate luciferase activity in the presence of vehicle, 
rapamycin and DMSO.  Furthermore, the activity observed in the NLuc-AIB-
RID/FKBP12-CLuc transfected cells appeared to be modulated by ligand treatment; 
the activity observed with rapamycin was approximately 40% of that observed with 
DMSO.   
 
Taken together, these findings indicate that it is possible to use the luciferase 
complementation assay to detect ERα-coregulator interactions, although the 
magnitude of the complementation, as well as ligand-independent interaction might 
reduce the utility of such an assay.  In order to determine the reasons for the low 
complementation observed in NLuc-AIB-RID/ER-CLuc transfections, an 
immunocytochemical analysis of co-transfected 293 cells was performed to determine 
their cellular localisation (Figure 3.9).   
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Figure 3.8 - Specificity of rapamycin and E2 induced luciferase fragment complementation. 4x104 
293H cells were transfected with 200ng NLuc-FRB, FKBP12-CLuc, NLuc-AIB-RID, as indicated.  
Cells were treated with vehicle (DMSO; V), 4x10-7M rapamycin (R) or 10-6M E2 (E) for 24 hours prior 
to quantification of luciferase activity in live cells using the IVIS 100.  (A) Captured image. (B) Data 
quantified from ROI measurements showing mean luciferase activities (n = 3).  Error bars represent the 
standard errors of the mean (SEM).  The ANOVA test was used to determine statistical significance 
(***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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Figure 3.9 - Immunofluorescence of NLuc-AIB-RID, ER-LBD-CLuc, ER-CLuc and endogenous 
ERα and AIB1. 4x104 293 cells were seeded in chamber slides prior to transfection with NLuc-AIB-
RID/ER-LBD-CLuc or NLuc-AIB-RID/ER-CLuc. Cells were treated with vehicle or 10-6M E2 for 24 
hours prior to staining with mouse-anti-ERα/Alexa Fluor 594 antibodies and rabbit anti-AIB1/Alexa 
Fluor 488 antibodies.  Slides were mounted with Prolong Gold Antifade with DAPI.  Photographs 
show ERα (red), AIB1 (green) and a merged image with DAPI stained nuclei (blue). Also shown is the 
immunofluorescence staining of endogenous ERα and AIB1 in MCF7 cells. 
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In MCF7 cells, the endogenous ERα and AIB1 are nuclear in both vehicle and E2 
treated populations (Figure 3.9).  Immunofluorescence staining for ERα and AIB1 in 
NLuc-AIB-RID/ER-LBD-CLuc transfected cells showed that the luciferase fusion 
proteins were cytoplasmic in the presence or absence of E2.  Although this is different 
from the localisation of the endogenous proteins, the luciferase fusion proteins are in 
the same cellular compartment and complementation is therefore possible.  However, 
the ER-CLuc fusion protein, in which the full length ERα is fused to CLuc, was 
nuclear, thus providing an explanation for the lack of luciferase complementation 
observed between nuclear ER-CLuc and cytoplasmic NLuc-AIB-RID (Figure 3.9).  
 
Following the immunocytochemical analysis of the fusion protein localization, I 
chose to continue to develop the truncated AIB-RID and ER-LBD split-luciferase 
assay while investigating the possibility of producing a full length ERα and AIB1 
split-luciferase assay in parallel. 
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3.4  Truncated ER-LBD-AIB-RID split-luciferase assay 
 
Having established that ER-LBD and AIB-RID luciferase fragment fusion proteins 
could be used to detect ERα-AIB1 interaction, it was desirable to optimise the assay 
to maximise its sensitivity.  Insertion of a flexible spacer between fusion proteins has 
previously been proposed to enhance native folding of fusion protein fragments by 
increasing the distance between, and therefore reducing any steric hindrance between, 
moieties (Newton et al., 1996, Arai et al., 2001, Arai et al., 2004)  To determine 
whether a flexible spacer would enhance the NLuc-AIB-RID and ER-LBD-CLuc 
split-luciferase assay, the constructs were modified to include 1 or 2 copies of a 
glycine rich flexible spacer (Figure 3.10A).  The spacer was made of an 
oligonucleotide encoding 2 repeats of a Gly-Gly-Gly-Gly-Ser sequence and was 
inserted into the BamHI site between the fusion proteins.  Glycine and serine rich 
flexible spacers have been frequently used to separate fusion proteins in luciferase 
fragment complementation assays (Kim et al., 2007a, Luker et al., 2004, Stefan et al., 
2007, Paulmurugan and Gambhir, 2003).   
 
As shown above, NLuc-AIB-RID and ER-LBD-CLuc interaction was stimulated by 
the addition of 10-6M E2 (Figure 3.10B).  No stimulation was observed with 10-9M 
E2. The addition of glycine spacers into ER-LBD-CLuc did not greatly influence 
interaction with NLuc-AIB-RID.  Neither did a single glycine spacer in NLuc-AIB-
RID aid interaction. However, a double spacer between the NLuc and AIB-RID 
protein fusions considerably improved complementation, even in the presence of 10-
9M E2.  The greatest activity was observed with NLuc-SS-AIB-RID and ER-LBD-SS-
CLuc. 
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Figure 3.10 - Influence of spacer insertion on NLuc-AIB-RID/ER-LBD-CLuc complementation. 
NLuc-AIB-RID and ER-LBD-CLuc were modified to contain one (S) or two (SS) copies of a glycine 
rich flexible spacer (A).  (B)  4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng 
of NLuc-(S/SS)-AIB-RID/ER-LBD-(S/SS)-CLuc as indicated.  Cells were treated with vehicle 
(ethanol; V), 10-9M or 10-6M E2 for 48 hours prior to quantification of luciferase activities.  Mean 
firefly luciferase activities (n = 3) normalized to Renilla luciferase activities are shown. Error bars 
represent the standard errors of the mean (SEM).  The ANOVA test was used to determine statistical 
significance. Asterisks above columns indicate differences +/- E2 are significant, asterisks on 
horizontal bars indicate that mean of 10-6M E2 treated cells is significantly different (***, p ≤ 0.001, 
**, p ≤ 0.01, *, p ≤ 0.05). 
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To further optimize the ER-LBD/AIB-RID split-luciferase assay, the impact of 
altering the protein-luciferase fragment fusions was investigated.  Previous studies 
have indicated that the relative orientation of protein fragments within a fusion can 
have a significant impact on reporter fragment complementation (Paulmurugan and 
Gambhir, 2007).  Accordingly, NLuc-ER-LBD and AIB-RID-CLuc fusion protein 
constructs were generated and 1 or 2 copies of the glycine rich flexible spacer were 
inserted between the fusions (Figure 3.11A). 
 
Transfection of 293 cells indicated that altering the orientation of the fusion proteins 
had a major impact on the E2 stimulated luciferase fragment complementation; 
incubation of cells transfected with NLuc-ER-LBD/AIB-RID-CLuc led to a 9-fold 
stimulation in luciferase activity in the presence of 10-6M E2 (Figure 3.11).  The 
sensitivity of the split-luciferase assay to the lower 10-9M E2 was also much greater in 
this orientation.  NLuc-ER-LBD/AIB-RID-CLuc transfected cells treated with 10-9M 
E2 showed a 6-fold increase in activity, which was 75% of the maximum signal 
observed with this construct pair.    
 
Of note, the signal intensity in NLuc-(S/SS)-ER-LBD/AIB-RID-(S/SS)-CLuc 
transfected cells was 10-fold less than in NLuc-(S/SS)-AIB-RID/ER-LBD-(S/SS)-
CLuc transfections (Figure 3.11B versus Figure 3.10B).   
 
Insertion of flexible spacers into NLuc-ER-LBD did not greatly influence the 
complementation observed with vehicle or E2.  However, inserting one or two copies 
of the flexible spacer into AID-RID-CLuc increased the complementation observed 
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Figure 3.11 - NLuc-ER-LBD/AIB-RID-CLuc complementation and the impact of spacer 
insertion. NLuc-ER-LBD and AIB-RID-CLuc constructs were produced and modified to contain one 
(S) or two (SS) copies of a glycine rich flexible spacer (A).  (B)  4x104 293 cells were transfected with 
50ng Renilla luciferase and 150ng of NLuc-(S/SS)-ER-LBD/AIB-RID-(S/SS)-CLuc as indicated.  
Cells were treated with vehicle (ethanol; V), 10-9M or 10-6M E2 for 48 hours prior to quantification of 
luciferase activities.  Mean firefly luciferase activities (n = 3) normalized to Renilla luciferase activities 
are shown. Error bars represent the standard errors of the mean (SEM).  The ANOVA test was used to 
determine statistical significance. Asterisks above columns indicate differences +/- E2 are significant, 
asterisks on horizontal bars indicate that mean of 10-6M E2 treated cells is significantly different (***, 
p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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with 10-6M E2.  This effect was only seen with NLuc-ER-LBD; in cotransfections 
with NLuc-S-ER-LBD or NLuc-SS-ER-LBD, spacer insertion into AIB-RID-CLuc 
had little impact on the complementation observed.   
 
In order to maximise the sensitivity of the ER-LBD/AIB-RID split-luciferase assay, I 
selected the construct pair with the greatest fold difference between signal states; 
NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells produced the largest fold 
increase in luciferase activity when treated with E2, more than a 10-fold increase in 
signal was observed with 10-6M E2 compared to vehicle.  However, the relatively low 
overall signal intensity with this construct pair might be problematic for in vivo 
imaging and for this reason NLuc-SS-ER-LBD/AIB-RID-SS-CLuc were also further 
characterised, as they represented the construct pair which provided the greatest 
overall luminescence.  
 
Initially, a more comprehensive E2 titration on NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells was undertaken 
(Figure 3.12).  Both split-luciferase construct pairs showed a dose dependent increase 
in luciferase activity with E2 treatment.  Near maximal stimulation was observed in 
the presence of 10-8M E2, with only small increases being observed at higher 
concentrations. As previously observed, the NLuc-ER-LBD/AIB-RID-SS-CLuc 
transfected cells appeared to be more sensitive to low concentrations of E2 than the 
NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected cells; a 2-fold induction was 
observed in presence of 10-10M E2 whereas the NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc transfected cells showed no discernable difference in activity at this E2  
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Figure 3.12 - E2 response of ER-LBD/AIB-RID split-luciferase constructs. 4x104 293 cells were 
transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-AIB-RID, ER-LBD-SS-CLuc, NLuc-
ER-LBD and AIB-RID-SS-CLuc, as indicated, in 96 well plates.  1.5x104 MELN cells were seeded 
into 96 well plates.  Cells were treated with vehicle (ethanol; V) or a range of E2 concentrations for 48 
hours prior to quantification of luciferase activities.  Mean firefly luciferase activity is shown 
normalised to Renilla luciferase activity (A+B) or protein concentration (C).  Error bars represent the 
standard errors of the mean (SEM).  The ANOVA test was used to determine statistical significance 
relative to vehicle treatment (***, p ≤ 0.001, **, p ≤ 0.01). 
 
 
 
  88
concentration.  As a comparison, the MELN cell line also exhibited a dose dependent 
increase in luciferase activity, but was more sensitive to low concentrations of E2 than 
either of the split-luciferase construct pairs; the MELN cell line showed more than 
70% of maximal activity after incubation with 10-10M E2.   
 
To further validate the ligand-dependent interaction between the ERα LBD and the 
AIB1 RID, the ERα LBD was mutated to replace the tyrosine residue at position 537 
with a serine residue (Y537S) to produce a mutant receptor that is reported to be 
constitutively active  (Weis et al., 1996, White et al., 1997). In a second mutant the 
leucine residues at positions 539 and 540 were mutated to alanine (L539/40A) to 
produce a receptor that is incapable of interacting with AIB1 (Danielian et al., 1992, 
Bai and Giguere, 2003). 
 
Transfection of the mutant constructs with their complementary AIB-RID constructs, 
produced results consistent with the assay premise that luciferase fragment 
complementation is driven by the ER-LBD and AIB-RID fragments (Figure 3.13).  
Transfection of the constitutively active Y537S mutant produced high levels of 
luciferase activity, in the absence and presence of E2 treatment, consistent with the 
described constitutive activity of the Y537S mutant and showing sustained interaction 
with the coactivator AIB1.  Mutation of the leucine residues (L539/40A) prevented 
the interaction of the ER-LBD and AIB-RID, and low luciferase activity was 
observed in the presence and absence of E2.  Western blot of cell lysates confirmed 
that the observed effects were not attributable to different levels of the proteins in 
cells. 
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Figure 3.13 - Y537S and L539/40A ER-LBD split-luciferase constructs. 4x104 293 cells were 
seeded in 96 wells plates and transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B).  Shown are the activities in the 
presence of increasing concentrations of E2, or in the absence of ligand (vehicle control; V) for the 
Y537S (grey bars) or L539A/L540A (white bars) mutants of the ER-LBD.  Cells were treated with 
vehicle (ethanol; V) or E2 for 48 hours prior to quantification of luciferase activities.  Mean firefly 
luciferase activities (n = 3) normalized to Renilla luciferase activities are shown. Error bars represent 
the standard errors of the mean (SEM).  Inset shows western blots for ERα and β-actin of cells 
transfected with wildtype, Y537S or L539A/L540A ER-LBD-SS-CLuc and NLuc-ER-LBD fusion 
proteins. 
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Having established the specificity of the E2 induced luciferase fragment 
complementation, the effect of the antiestrogens OHT and ICI was investigated 
(Figure 3.14).  As expected, both inhibitors produced a dose dependent decrease in 
luciferase activity.  This was very similar to the results obtained for the MELN cell 
line, which showed luciferase activity below vehicle levels when treated with 
antiestrogens at concentrations of 10-7M or 10-6M (Figure 3.2).  
 
Western blot analysis of lysates from 293 cells transfected with either NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc or NLuc-ER-LBD/AIB-RID-SS-CLuc showed that levels of 
neither the ER-LBD nor the AIB-RID fusion proteins were significantly altered with 
ligand treatment (Figure 3.15).   
 
To further characterise the luciferase complementation, a time-course of activity was 
carried out using 293 cells transfected with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc or 
NLuc-ER-LBD/AIB-RID-SS-CLuc or MELN cells, which were treated with 10-6M 
E2 for increasing periods of time, up to a maximum of 48 hours (Figure 3.16).  The 
results show that the split-luciferase transfected cells exhibit a near maximal response 
to E2 within two hours.  The protein fragment complementation-dependent signal 
from the split-luciferase reporters was observed sooner than the transcription-
dependent luciferase signal in the MELN cells in response to E2.  However, there 
were small differences between the two split-luciferase construct pairs; the NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc transfected cells produced 60% of maximal activity after 
2 hours E2 incubation whereas the NLuc-ER-LBD/AIB-RID-SS-CLuc transfected 
cells appeared slightly more sensitive to E2 and produced 80% of their maximal 
activity after 2 hours of E2 incubation. 
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Figure 3.14 - Modulation of ER-LBD/AIB-RID split-luciferase E2 response by OHT and ICI. 
4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-AIB-RID/ER-
LBD-SS-CLuc (A+C) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B+D) in 96 well plates.  Cells were 
treated with ethanol, 10-9M E2 or 10-9M E2 and a range of OHT (A+B) or ICI (C+D) concentrations for 
48 hours prior to quantification of luciferase activities.  Mean firefly luciferase activities (n = 3) 
normalized to Renilla luciferase activities are shown. Error bars represent the standard errors of the 
mean (SEM).  The ANOVA test was used to determine statistical significance relative to E2 treatment 
(***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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Figure 3.15 - Expression of ER-LBD and AIB-RID fusion proteins in E2, OHT and ICI treated 
cells. Protein lysates prepared from 293 cells transfected with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc 
(A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B) cells treated with vehicle (ethanol; V), 10-6M E2, 10-6M 
OHT or 10-6M ICI were separated by SDS-PAGE and immunoblotted using AIB1, ERα or β-actin 
antibodies.   
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Figure 3.16 - Time-course of E2 response in ER-LBD/AIB-RID split-luciferase transfected and 
MELN cells. 4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B) in 96 well plates.  1.5x104 
MELN cells were seeded into 96 well plates (C).  At given times, vehicle (ethanol) or E2 was added to 
wells to a final concentration of 10-6M.  Mean luciferase activities (n = 3) are shown, normalized to 
Renilla luciferase activity (A+B) or total protein (C). Error bars represent the standard errors of the 
mean (SEM).  The ANOVA test was used to determine statistical significance relative to vehicle 
treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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A further time-course investigation showed that both split-luciferase construct pairs 
produced a discernable response to E2 within 15 minutes of ligand addition; a 1.5-fold 
and 2.4-fold increase in signal was observed for NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells respectively (Figure 
3.17).   
 
To determine whether antiestrogens can inhibit the E2-stimulated ER-LBD-AIB-RID 
interaction, 293 cells were transfected with the NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc or NLuc-ER-LBD/AIB-RID-SS-CLuc and luciferase fragment 
complementation was stimulated with 10-9M E2 for 24 hours.  10-6M OHT was 
subsequently added for different durations to determine whether the complemented 
luciferase activity was affected (Figure 3.18).  Both split-luciferase pairs showed a 
decrease in the E2 signal after 2 hours OHT incubation, although the degree of signal 
inhibition differed; 20% and 50% signal reduction was observed in NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc respectively.  After 2 
hours, the signal in the NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells continued 
to decline rapidly in response to OHT; 4 hours OHT incubation reduced the signal to 
a little over that observed with vehicle and full signal ablation occurred after just 6 
hours.   
 
The signal in the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected cells declined 
more slowly; a 50% decrease was observed after 4 hours but full signal ablation 
required between 10 and 24 hours incubation.  The MELN luciferase signal was much 
slower to decline; no difference was seen after 2 hours, a 35% reduction was achieved 
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Figure 3.17 - Minute time-course of E2 response in ER-LBD/AIB-RID split-luciferase constructs. 
4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-AIB-RID/ER-
LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B) in 96 well plates.  At given times, 
vehicle (ethanol) or 10-6M E2 was added to wells. Mean firefly luciferase activities (n = 3) normalized 
to Renilla luciferase activities are shown. Error bars represent the standard errors of the mean (SEM). 
The ANOVA test was used to determine statistical significance relative to vehicle treatment (***, p ≤ 
0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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Figure 3.18 - Time-course of E2 signal ablation in ER-LBD/AIB-RID split-luciferase transfected 
and MELN cells. 4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng of NLuc-
SS-AIB-RID/ER-LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B) in 96 well plates.  
1.5x104 MELN cells were seeded into 96 well plates (C).  After 24 hours incubation with 10-9M E2, 
vehicle (ethanol) or 10-6M OHT was added to wells for different periods of time.  Mean firefly 
luciferase activities (n = 3) is shown normalised to Renilla luciferase activity (A+B) or protein 
concentration (C).  Error bars represent the standard errors of the mean (SEM).  The ANOVA test was 
used to determine statistical significance relative to E2 treatment (***, p ≤ 0.001, **). 
 
 
 
 
 
  97
after 10 hours and after 24 hours OHT incubation the signal still had not reduced to 
vehicle levels. 
 
I proceeded to perform a minute time-course of signal ablation with the NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells 
(Figure 3.19).  Results collected from both the split-luciferase constructs indicated a 
reduction in luciferase fragment complementation within 15 minutes of OHT 
addition.  The NLuc-SS-AIB-RID/ER-LBD-SS-CLuc constructs showed almost 20% 
signal reduction while the NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells 
showed just over 30% signal reduction, although the signal in these cells was greater 
at the 30 and 60 minute time points.   
 
There were, however, some inconsistencies in the results collected in the ‘minute’ 
time-course experiment.  The fold induction observed with E2 alone was less than that 
observed in previous experiments; 2.4-fold and 4-fold for NLuc-SS-AIB-RID/ER-
LBD-SS-CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells respectively.  
Furthermore, the signal reduction observed after 2 and 4 hours in the minute time-
course (Figure 3.19) was less than that observed in the hour time-course (Figure 3.18).  
The NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected cells showed 25% signal 
reduction after 2 hours OHT incubation in the minute time-course, compared to 
almost 50% reduction in the hour time-course experiment.  Similarly, the NLuc-ER-
LBD/AIB-RID-SS-CLuc transfected cells showed 35% and 65% signal reduction 
after 2 and 4 hours OHT incubation in the minute time-course experiment compared 
to 50% and 85% reduction in the hour time-course experiment. 
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Figure 3.19 - Minute time-course of E2 signal ablation in ER-LBD/AIB-RID split-luciferase 
constructs. 4x104 293 cells were transfected with 50ng Renilla luciferase and 150ng of NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B) in 96 well plates. After 24 
hours incubation with 10-9M E2, vehicle (ethanol) or 10-6M OHT was added to wells for different 
periods of time.  Mean firefly luciferase activities (n = 3) normalized to Renilla luciferase activities are 
shown. Error bars represent the standard errors of the mean (SEM).  The ANOVA test was used to 
determine statistical significance relative to E2 treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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 Although I had obtained some unexpected results, the ER-LBD/AIB-RID split-
luciferase constructs appeared to be showing much promise as a method for reporting 
on ER-AIB interaction and ERα activity, and so I chose to examine the ability to 
modulate their activity in vivo in xenograft models. To allow direct comparison of the 
two split-luciferases in vivo, NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-
LBD/AIB-RID-SS-CLuc transiently transfected 293 cells were implanted into each 
mouse on opposing flanks (Figure 3.20A).  The number of cells implanted was 
adjusted to minimise differences in signal between the reporters.  Mice had E2 or 
placebo pellets implanted 5 days previously and were treated with ICI or placebo 
immediately after cell implantation and again 20 hours later.  Luciferase activity was 
quantified 24 hours after cell implantation (Figure 3.20 B and C). 
 
The results show that an E2 induced increase in luciferase activity could be observed 
with both NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-LBD/AIB-RID-SS-
CLuc transfected cells in vivo.  No luciferase activity above background levels was 
discernable in the double placebo treated mice whereas E2 treatment produced ROI 
readings of 1.6x105 and 5x104 photons/second in NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc and NLuc-ER-LBD/AIB-RID-SS-CLuc cell populations, respectively.  The 
signal in mice treated with E2 and ICI was less in both cell populations, although the 
degree of reduction differed considerably.  The NLuc-ER-LBD/AIB-RID-SS-CLuc 
transfected cells showed a moderate 20% decrease in signal whereas the NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc transfected cells showed 80% decrease in activity.  Most 
unexpectedly, the greatest luciferase activity with both reporters was observed in mice 
treated with ICI and placebo pellets.  This could be a reflection of ICI performing as a  
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Figure 3.20– In vivo modulation of ER-LBD/AIB-RID split-luciferases by E2 and ICI. 2x106 
NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and 8x106 NLuc-ER-LBD/AIB-RID-CLuc transfected cells 
were subcutaneous injected into the left and right flank of nude mice (A) that had 0.72mg/60 day E2 or 
placebo pellets implanted 5 days previously.  Mice were treated with 5mg ICI or peanut oil placebo by 
subcutaneous injection immediately after cell implantation and again 20 hours later.  24 hours after cell 
implantation, mice were imaged using the IVIS 100.  Representative images (B) and quantified data 
(C) are shown for each treatment and cell line (n=5; error bars are SEM).  P = placebo, I = ICI, E = E2, 
E+I = E2 and ICI. 
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E2 agonist, as previously demonstrated in bone and neuronal cells (Sibonga et al., 
1998, Zhao et al., 2006).   
 
I proceeded to examine whether I could achieve modulation of the E2 signal by OHT 
in vivo.  Once again, NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-
LBD/AIB-RID-SS-CLuc transfected cells were injected into opposing flanks, but this 
time MELN cells were also injected into the scruff of the mice (Figure 3.21A).  The 
mice had E2 or placebo and 2x5mg OHT or placebo pellets implanted 5 days 
previous.  Luciferase activity in mice was imaged 24 hours after cell implantation 
(Figure 3.21B and C). 
 
Though the same quantity of NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-
LBD/AIB-RID-SS-CLuc transfected cells were injected as in the ICI in vivo 
experiment, in this experiment double placebo treated mice showed luciferase activity 
well above background levels.  However, the signal with E2 treatment was also much 
higher in this experiment, 60- and 52-fold that observed in the ICI in vivo experiment 
for the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and NLuc-ER-LBD/AIB-RID-SS-
CLuc constructs, respectively.   
 
For both the split-luciferase reporters, approximately a 7-fold increase in luciferase 
activity was observed with E2 versus placebo treatment in vivo, this compares to an 
average of 4- and 10-fold in vitro for the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and 
NLuc-ER-LBD/AIB-RID-SS-CLuc constructs.  The MELN cells showed more than 
20-fold E2 signal induction in vivo, which compares to an average of 4-5 fold in vitro.  
The MELN signal in the E2 and OHT treated mice was approximately half that seen  
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Figure 3.21– In vivo modulation of ER-LBD/AIB-RID split-luciferase transfected and MELN 
cells by E2 and OHT. 5x105 MELN, 2x106 NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected 293 
and 8x106 NLuc-ER-LBD/AIB-RID-CLuc transfected cells were subcutaneous implanted into nude 
mice (A).  0.72mg/60 day E2/placebo and/or 2x5mg/60 day OHT/placebo pellets implanted into mice 5 
days previously.  24 hours after cell implantation, mice were imaged using the IVIS 100.  
Representative images (B) and quantified data (C) are shown for each treatment and cell line (n=5).  P 
= placebo, T(am) = Tamoxifen, E(2) = E2, E(2) + T(am) = E2 and Tamoxifen. The ANOVA test was 
used to determine statistical significance (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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in the E2 only mice, indicating that OHT delivery had been successful.  However, 
neither of the split-luciferase reporters showed a decrease in signal intensity with 
OHT treatment, indeed, both reporters showed greater luciferase activity in the E2 
andOHT versus E2 alone treated mice; the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc 
transfected cells showed a 40% increase whereas the NLuc-ER-LBD/AIB-RID-SS-
CLuc transfected cells showed a 25% increase.  This is in contrast to the signal in the 
mice which received OHT but no E2; the signal relative to double placebo mice was 
approximately equal in the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc cells, was 40% 
less in the NLuc-ER-LBD/AIB-RID-SS-CLuc cells, but almost 3-fold higher than the 
double placebo mice in the MELN cells. 
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3.5  Full length ERα-AIB1 split-luciferase assay 
 
In parallel to the development and characterization of the truncated ER-LBD/AIB-
RID split-luciferase constructs, I also chose to produce full length ERα and AIB1 
constructs; inclusion of the whole proteins ought to make the split-luciferases more 
receptive to the intracellular signalling which regulates the activity of the endogenous 
ERα and AIB1, and thus could produce a better reporter of ERα-coregulator 
interaction.     
 
Split-luciferase constructs were produced with full length ERα and AIB1 in both 
orientations (i.e. fused to NLuc and CLuc).  Initial transfections of complementary 
full length constructs produced low luciferase activity.  In an effort to optimize the 
transient transfection, increasing quantities of the larger AIB1 fusion protein construct 
were used in the transfections (Figure 3.22). 
 
In both orientations, increasing the ratio of the AIB1 fusion construct relative to the 
ERα fusion construct, increased the difference in signal between vehicle and E2 
treated cells.  The increase in luciferase activity observed with E2 addition in the 
NLuc-AIB/ER-CLuc transfected cells increased from 2.3-fold with a 1:1 ratio to 3.5-
fold with a 32:1 ratio of AIB to ER fusion protein.  In the NLuc-ER/AIB-CLuc 
transfected cells, the increase in signal observed with E2 went from 1.5-fold with a 
1:1 ratio to 2.5-fold with a 16:1 ratio of AIB1 to ER fusion protein.  However, with 
both protein orientations, the higher ratios of AIB1 to ER fusion protein, which 
produced the greatest fold increase with E2 addition, produced less overall 
luminescence.  This was especially pronounced with the NLuc-ER/AIB-CLuc 
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Figure 3.22 - Ratio transfections of full length ER/AIB split-luciferase reporters. 4x104 293 cells 
were seeded in 96 well plates and transfected with 50ng Renilla luciferase and 150ng of NLuc-
AIB/ER-CLuc (A) or NLuc-ER/AIB-CLuc (B) in different ratios. Cells were treated with vehicle 
(ethanol) or 10-6M E2 for 48 hours prior to quantification of luciferase activities.  Mean firefly 
luciferase activities (n = 3) normalized to Renilla luciferase activities are shown. Error bars represent 
the standard errors of the mean (SEM).  A t-test was used to determine statistical significance to 
between E2 and vehicle treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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 transfected cells where the signal intensity was only just above background levels. 
 
Immunofluorescence of NLuc-AIB/ER-CLuc and NLuc-ER/AIB-CLuc transfected 
cells confirmed that all four of the full-length fusion proteins were nuclear in 
localization (Figure 3.23).  The results also indicated that very few cells expressed 
both of the fusion proteins together.   
 
Given the low luminescence of the full length constructs and our experience with the 
truncated ER-LBD/AIB-RID split-luciferases, where the stable cell line 
characteristics were different to transient transfection results (Section 3.6), I decided 
to produce stable cell lines with the full length ER/AIB1 constructs prior to full 
characterisation.  It had been shown that the constructs complemented in the presence 
of E2, and so it was felt that it would be more efficient to characterise the constructs 
once they were stably expressed.  
 
In order to appreciate the agonist/antagonist effects of ERα ligands in the breast, bone 
and endometrium, efforts were made to produce MCF7, U2OS and Ishikawa cell lines 
which stably expressed NLuc-SS-AIB/ER-SS-CLuc or NLuc-SS-ER/AIB-SS-CLuc.  
Initially, transfections were performed with both constructs simultaneously.  Colonies 
were assessed for luminescence in the presence of E2 with the IVIS 100 and more 
sensitive Topcount luminometer.  Expression of the fusion proteins was assessed by 
western blotting.  Though colonies formed which were resistant to the two antibiotics, 
none screened positive for luciferase activity or dual fusion protein expression.  
Western blotting indicated that some clones expressed detectable quantities of one of 
the fusion proteins, and transient transfection of the complementary fusion protein  
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Figure 3.23 - Immunofluorescence of full length ER/AIB split-luciferase reporters. 4x104 293 cells 
were seeded into chamber slides prior to transfection with NLuc-AIB/ER-CLuc or NLuc-ER/AIB-
CLuc. Cells were treated with vehicle (ethanol) or 10-6M E2 for 24 hours prior to staining with mouse-
anti-ERα/Alexa Fluor 594 antibodies and rabbit anti-AIB1/Alexa Fluor 488 antibodies.  Slides were 
mounted with Prolong Gold Antifade with DAPI.  Photographs show ERα (red), AIB1 (green) and a 
merged image with DAPI stained nuclei (blue). 
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 into these cells would produce luciferase activity which would increase in the 
presence of E2 (Figure 3.24).  Attempts were made to establish stable expression of 
the complementary fusion protein in these cells, however, similar problems of 
antibiotic resistance without luminescence were encountered.   
 
Due to time constraints, it was not possible to generate cell lines which stably 
expressed NLuc-SS-AIB and ER-SS-CLuc or NLuc-SS-ER and AIB-SS-CLuc. 
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Figure 3.24 - U2OS NLuc-SS-AIB/ER-SS-CLuc stable cell lines. U2OS cell were transfected with 
NLuc-SS-AIB/ER-SS-CLuc.  Western blotting indicated that colony #16 stably expressed NLuc-SS-
AIB (A).  Colony #16 cells transiently transfected with 50ng Renilla luciferase and 150ng of ER-SS-
CLuc were treated with vehicle (ethanol) or 10-6M E2 for 48 hours prior to quantification of luciferase 
activities (B).  Mean firefly luciferase activities (n = 4) normalized to Renilla luciferase activities are 
shown. Error bars represent the standard errors of the mean (SEM).  A t-test was used to determine 
statistical significance (***, p ≤ 0.001). 
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3.6  Truncated ER-LBD/AIB-RID split-luciferase reporters and the 
tissue specific actions of ERα ligands 
 
One of the principal aims in developing the ER-AIB1 split-luciferase reporters was to 
establish a novel method for imaging the tissue specific actions of SERMs.  In order 
to achieve this, it was our intention to stably transform breast (MCF7), bone (U2OS) 
and endometrial (Ishikawa) cell lines with the split-luciferase reporters to determine 
whether they complement in a context specific manner when treated with different 
ligands.   
 
3.6.1  MCF7 stable cell lines 
 
To produce the stable cell line representing breast tissue, MCF7 cells were transfected 
with NLuc-ER-LBD and AIB-RID-SS-CLuc.  These constructs had shown the 
greatest fold induction in response to E2 and the fastest response to ligand in transient 
transfections.  Both constructs were simultaneously transfected and transformed cells 
were selected for with antibiotics.  Colonies which formed in the presence of selective 
antibiotics were propagated and screened for luciferase activity using the IVIS 100.  
The E2 induced complementation of positive clones was examined by incubation with 
10-9M  and 10-6M E2 (Figure 3.25).   
 
Examination of the luciferase signal in 6 clones showed considerable variation in 
signal, even though the same constructs had been transfected.  The signal intensity 
ranged from tens to hundreds of photon counts per second.  The fold induction 
observed with E2 addition also varied from 1.6-fold in colony #6 to 3.8-fold in colony 
#1.  In all cases, the fold induction observed with E2 was considerably less than the  
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Figure 3.25 - E2 response of MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc stable cell lines. 1.5x104 
cells were seeded in 96 well plates prior to treatment with vehicle (ethanol; V) or 10-9M or 10-6M E2 
for 48 hours.  Luciferase activity was quantified in live cells after addition of 150µg/ml D-luciferin.  
Graphs show mean firefly luciferase activities (n = 3).  Error bars represent the standard errors of the 
mean (SEM). SEM (n=3). The ANOVA test was used to determine statistical significance (***, p ≤ 
0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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average of 10-fold observed with transient transfection of NLuc-ER-LBD and AIB-
RID-SS-CLuc into 293 cells.     
 
Based on their signal intensity and fold increase in signal with E2, MCF7 NLuc-ER-
LBD/AIB-RID-SS-CLuc #1 and #4 were selected for further characterisation.  A 
more comprehensive titration of E2 showed that cells from colony #1 and #4 reached 
signal plateau in the presence of 10-9M and 10-8M E2 respectively (Figure 3.26).  In 
transient transfections of NLuc-ER-LBD and AIB-RID-SS-CLuc in 293 cells the 
maximum signal intensity was observed with 10-6M E2.  The maximum stimulation of 
by E2 was 2.6- and 2-fold vehicle luciferase activity for colony #1 and #4 
respectively.  By way of comparison, the MELN cells showed a 3.9-fold increase in 
signal when incubated with 10-10M E2.  The E2 titration results also suggested that the 
split-luciferase reporters expressed in an MCF7 background continue to be less 
responsive to low levels of E2 when compared to the MELN cells; the MELN cell 
line showed almost 80% of their maximum signal with 10-12M E2 whereas the split-
luciferase reporters showed little, if any, increase above vehicle levels at 10-12 M E2.   
 
Incubation of the split-luciferase stable cell lines with OHT and ICI indicated that the 
E2 response of the split-luciferase stable cell lines was modulated by antiestrogens 
(Figure 3.27).  With both OHT and ICI, the E2 induced increase in signal was ablated 
to vehicle levels with 10-8M inhibitor and higher concentrations reduced the signal 
below background levels.  In transiently transfected 293 cells 10-7M inhibitor was 
required to reduce the signal to vehicle levels and in MELN cells the signal was 
reduced to vehicle levels with inhibitor concentrations between 10-8M  and 10-7M. 
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Figure 3.26 - E2 response of MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 and #4.  1.5x104 MELN 
(A) or 2x104 MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (B) or #4 (C) cells were treated vehicle 
(ethanol; V) or increasing concentrations of E2 for 48 hours prior to quantification of luciferase 
activity.  Mean firefly luciferase activities (n = 3) normalized to total protein are shown. Error bars 
represent the standard errors of the mean (SEM).  The ANOVA test was used to determine statistical 
significance relative to vehicle treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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Figure 3.27 – Modulation of MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 and #4 E2 response by 
OHT and ICI. 2x104 MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (A+B) or #4 (C+D) cells were 
treated vehicle (ethanol) or 10-9M E2 and different concentrations of OHT (A+C) or ICI (B+D) for 48 
hours.  Mean firefly luciferase activities (n = 3) normalized to total protein are shown. Error bars 
represent the standard errors of the mean (SEM).  The ANOVA test was used to determine statistical 
significance relative to E2 treatment (***, p ≤ 0.001, *, p ≤ 0.05). 
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 An investigation of the signal dynamics in the stably transfected MCF7 cell lines 
showed that cells from both colonies produced approximately 65% of their maximum 
signal after 2 hours incubation with E2 (Figure 3.28A and B).  With longer E2 
incubations the luciferase signal steadily increased; after 8 hours E2 incubation 95% 
and 90% of maximum signal had been induced in the MCF7 NLuc-ER-LBD/AIB-
RID-SS-CLuc #1 and #4 cells respectively.  In 293 cells transiently transfected with 
NLuc-ER-LBD and AIB-RID-SS-CLuc, 80% of signal was induced with 2 hours E2 
incubation (Figure 3.16, Section 3.4).   
 
Investigation of the OHT signal ablation in the MCF7 NLuc-ER-LBD/AIB-RID-SS-
CLuc #1 and #4 cells showed that approximately 20% and 15% of the E2 induced 
signal was lost after 2 hours incubation with OHT (Figure 3.28 C and D).  This is in 
contrast to the transiently transfected 293 cells, where approximately 50% of the 
signal was lost after 2 hours.  However, in common with the transient transfection 
results, OHT incubation of 4 hours reduced the E2 induced signal to a little more than 
vehicle levels and 6 hours reduced the signal below vehicle levels. 
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Figure 3.28 - Signal dynamics of MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 and #4. .  2x104 
MCF7 NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (A+C) or #4 (B+D) cells were seeded into 96 well 
plates.  Cells were incubated with 10-6M E2 for increasing periods of time (A+B) or 10-9M E2 for 24 
hours prior to addition of 10-6M OHT for increasing periods of time (C+D).  Mean firefly luciferase 
activities (n = 3) normalized to total protein are shown.  Error bars represent the standard errors of the 
mean (SEM).  The ANOVA test was used to determine statistical significance relative to E2 treatment 
(***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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3.6.2  U2OS stable cell lines 
 
Having observed that results obtained with the MCF7 NLuc-ER-LBD/AIB-RID-SS-
CLuc stable cell lines differed from transient transfection results obtained with the 
same constructs, I decided to produce U2OS stable cell lines with both fusion protein 
orientations - NLuc-ER-LBD/AIB-RID-SS-CLuc and NLuc-SS-AIB-RID/ER-LBD-
SS-CLuc.  Using the same selection procedure, five stably transfected U2OS colonies 
were obtain; one colony was transfected with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc 
and 4 colonies were transfected with NLuc-ER-LBD/AIB-RID-SS-CLuc.  To assess 
the stable cell lines, their luciferase activity was examined in the presence of vehicle 
and a range of E2 concentrations (Figure 3.29). 
 
In all five of the U2OS stable cell lines, E2 stimulated a much greater fold increase in 
luciferase activity than in the MCF7 stable cell lines; the average maximum signal 
was 8-fold that observed with vehicle.  The NLuc-SS-AIB-RID/ER-LBD-SS-CLuc 
colony produced the greatest fold induction with E2; 12 times the vehicle signal was 
observed in the presence of 10-6M E2.  The NLuc-ER-LBD/AIB-RID-SS-CLuc 
transfected colonies produced between 7- and 9-fold increases in signal intensity with 
10-8M and 10-6M E2.  In transient transfection of 293 cells, E2 stimulation was 
greatest with NLuc-ER-LBD and AIB-RID-SS-CLuc, averaging between 10- and 12-
fold the vehicle signal, while lower signal increases of between 5- and 8- fold were 
observed with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected cells: the opposite 
scenario to that observed in the U2OS stable cell lines.  Western blotting confirmed 
co-expression of NLuc and CLuc ER and AIB1 fusion proteins of the expected sizes 
(Figure 3.30).   
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Figure 3.29 - E2 response of U2OS stable cell lines. 6x103 U2OS cells stably transfected with NLuc-
SS-AIB-RID/ER-LBD-SS-CLuc (A) or NLuc-ER-LBD/AIB-RID-SS-CLuc (B-E) were treated vehicle 
(ethanol; V) or increasing concentrations of E2 for 48 hours prior to quantification of luciferase 
activity.  Graphs show mean firefly luciferase activities (n = 3).  Error bars represent the standard errors 
of the mean (SEM). The ANOVA test was used to determine statistical significance relative to vehicle 
treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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Figure 3.30 - Western blot of fusion proteins in U2OS stable cell lines. 10µg of lysate from U2OS 
or U2OS cell lines stably transfected with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc or NLuc-ER-
LBD/AIB-RID-SS-CLuc were separated by SDS-PAGE and blotted for using rabbit anti-AIB1, mouse 
anti-ERα or mouse anti-β-actin antibodies.   
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From the E2 titration experiments, I chose to further characterise NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc colony #1 and NLuc-ER-LBD/AIB-RID-SS-CLuc colonies 
#1 and #4; these colonies showed the greatest induction with E2 and represented both 
fusion protein orientations.  NLuc-ER-LBD/AIB-RID-SS-CLuc colony #1 was further 
characterised as well as NLuc-ER-LBD/AIB-RID-SS-CLuc colony #4 because it 
reached a signal maximum at 10-8M E2 whereas NLuc-SS-AIB-RID/ER-LBD-SS-
CLuc colony #1 and as NLuc-ER-LBD/AIB-RID-SS-CLuc colony #4 both showed 
maximum signal intensity with 10-6M E2. 
 
Incubation of U2OS NLuc-SS-AIB-RID/ER-LBD-SS-CLuc colony #1 and NLuc-ER-
LBD/AIB-RID-SS-CLuc colonies #1 and #4 with 10-9M E2 and increasing 
concentrations of OHT or ICI indicated that the luciferase activity of the U2OS stable 
cell lines was modulated by antiestrogens in a dose dependent manner (Figure 3.31).  
With both inhibitors, E2 induced luciferase activity was reduced to vehicle levels with 
inhibitor concentrations of 10-7M or above.  Although OHT is thought to be a mild 
agonist in bone cells, no evidence of this effect was observed; OHT and ICI, a pure 
antiestrogen, appeared to affect the reporters in a  very similar fashion.  If any 
difference was observed, it suggested that OHT was a more potent inhibitor than ICI.  
 
I proceeded to investigate the dynamics of the luciferase signal in the U2OS stable 
cell lines.  Incubation of U2OS NLuc-SS-AIB-RID/ER-LBD-SS-CLuc colony #1 and 
NLuc-ER-LBD/AIB-RID-SS-CLuc colonies #1 and #4 with 10-6M E2 for increasing 
periods of time indicated that luciferase activity increased as a function of E2 
incubation time (Figure 3.32 A-C).   
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Figure 3.31 - Modulation of E2 response in U2OS stable cell lines by OHT and ICI. 6x103 U2OS 
NLuc-SS-AIB-RID/ER-LBD-SS-CLuc #1 (A), or U2OS NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (B) or 
#4 (C) cells were treated vehicle (ethanol) or 10-9M E2 and different concentrations of OHT (A-C) or 
ICI (D-F) for 48 hours prior to quantification of luciferase activity.  Graphs show mean firefly 
luciferase activities (n = 3).  Error bars represent the standard errors of the mean (SEM). The ANOVA 
test was used to determine statistical significance relative to E2 treatment (***, p ≤ 0.001, **, p ≤ 0.01, 
*, p ≤ 0.05). 
 
 
 
  122
  
U2OS NLuc-SS-AIB-RID
/ER-LBD-SS-CLuc #1
0 2 4 6 8 2448
0
200
400
600
800
1000
E2 incubation (hrs)
C
o
u
n
ts
/s
e
c
o
n
d
U2OS NLuc-ER-LBD/
AIB-RID-SS-CLuc #1
0 2 4 6 8 2448
0
100
200
300
400
E2 incubation (hrs)
C
o
u
n
ts
/s
e
c
o
n
d
U2OS NLuc-ER-LBD/
AIB-RID-SS-CLuc #4
0 2 4 6 8 2448
0
200
400
600
800
1000
E2 incubation (hrs)
C
o
u
n
ts
/s
e
c
o
n
d
U2OS NLuc-SS-AIB-RID
/ER-LBD-SS-CLuc #1
0
200
400
600
800
C
o
u
n
ts
/s
e
c
o
n
d
U2OS NLuc-ER-LBD/
AIB-RID-SS-CLuc #1
0
100
200
300
400
C
o
u
n
ts
/s
e
c
o
n
d
U2OS NLuc-ER-LBD/
AIB-RID-SS-CLuc #4
0
300
600
900
1200
C
o
u
n
ts
/s
e
c
o
n
d
+
24
E2
OHT 
(hours)
A B C
D E F
++++--
+- - 2 4 8
+
24
E2
OHT 
(hours)
++++--
+- - 2 4 8
+
24
E2
OHT 
(hours)
++++--
+- - 2 4 8
***
***
***
***
***
*
**
**
***
***
***
***
***
***
*
*** ***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
 
 
Figure 3.32 – Time-course of luciferase signal in U2OS stable cell lines. 6x103 U2OS NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc #1 (A+D), or U2OS NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (B+E) or #4 
(C+F) cells were seeded in 96 well plates.  Cells were treated with 10-6M E2 for increasing durations 
(A-C) or 10-9M E2 for 24 hours before addition of concentrated OHT (final concentration 10-6M; D-F) 
for different durations.  Graphs show mean firefly luciferase activities (n = 3).  Error bars represent the 
standard errors of the mean (SEM). SEM (n=3). The ANOVA test was used to determine statistical 
significance relative to E2 treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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The luciferase activity in the entire panel of U2OS stable cell lines increased 
approximately 2-fold after 2 hours E2 incubation, which represented 35-40% of the 
maximum luciferase activity observed.  The NLuc-SS-AIB-RID/ER-LBD-SS-CLuc 
#1 cells were the slowest to respond to E2; 8 hours ligand incubation produced 50% 
of the maximum signal and the signal continued to increase with ligand incubations 
up to 48 hours.  The NLuc-ER-LBD/AIB-RID-SS-CLuc #1 and #4 cells were faster to 
respond to the E2 signal; 50-60% of maximum signal was achieved after 6 hours E2 
incubation and the maximum was reached after 8 and 24 hours for NLuc-ER-
LBD/AIB-RID-SS-CLuc #1 and #4 cells, respectively.  Although a change in signal 
was discernable in all the U2OS stable cell lines after 2 hours, in general the E2 
stimulated increase in luciferase activity was much slower than in the MCF7 stable 
and transiently transfected 293 cells, which showed 60-80% of maximum signal after 
2 hours E2 incubation.   
 
I next investigated the duration required for OHT to ablate the E2 induced luciferase 
activity in the U2OS stable cell lines (Figure 3.32 D-F).  The results indicate that 
although the luciferase signal is slow to establish itself in response to E2 in the U2OS 
stable cell lines, it declines very rapidly in response to OHT.  In the NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc #1 cells, a 35% reduction in signal intensity was observed 
after 2 hours OHT incubation and full signal ablation occurred after just 4 hours.  In 
the NLuc-ER-LBD/AIB-RID-SS-CLuc #1 and #4, the signal was reduced below 
vehicle levels after just 2 hours OHT incubation.  In previous experiments, signal 
ablation required 4-6 hours with the NLuc-ER-LBD/AIB-RID-SS-CLuc constructs in 
the MCF7 stable and in 293 transient transfections and the NLuc-SS-AIB-RID/ER-
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LBD-SS-CLuc constructs required more that 10 hours for full signal ablation in 
transient transfection experiments.   
 
3.6.3  Reporting of the tissue specific agonist actions of OHT 
 
As previously noted, experiments investigating the antiestrogen modulation of the E2 
induced luciferase signal in the U2OS stable cell lines produced results very similar to 
those seen in MCF7 cells.  In order to more closely examine whether I could discern 
any differences in the actions of the SERM OHT and pure antiestrogen ICI in the 
U2OS split-luciferase reporters, I titrated both compounds individually without E2 
(Figure 3.33).   
 
Incubation of U2OS stable cell lines with increasing concentrations of OHT or ICI 
appeared to confirm that both inhibitors have the same affect on ER-AIB1 interaction; 
in all but one instance, addition of the inhibitor reduced luciferase activity below that 
of vehicle treatment.  Treatment of U2OS NLuc-SS-AIB-RID/ER-LBD-SS-CLuc #1 
cells with 10-10M OHT did increase luciferase activity above vehicle levels, but this 
was only seen with a single stable cell line at a single OHT dose and could be due to 
experimental error.  The remaining results appeared to suggest, that if any differences 
could be discerned between the inhibitors, lower concentrations of OHT were more 
potent than low concentrations of ICI. 
 
Due to time constraints, I was unable to produce stably transfected Ishikawa cell lines 
to determine whether the agonist action of OHT in endometrial cells could be 
observed using the ER-LBD/AIB-RID split-luciferase assay. However, transient           
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Figure 3.33 - Titration of OHT and ICI on U2OS stable cell lines. 6x103 U2OS NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc #1 (A+D), or U2OS NLuc-ER-LBD/AIB-RID-SS-CLuc #1 (B+E) or #4 (C+F) 
cells were treated with vehicle (ethanol; V) or increasing concentrations of OHT (A-C) or ICI (D-F) for 
48 hours prior to quantification of luciferase activity.  Graphs show mean firefly luciferase activities (n 
= 3).  Error bars represent the standard errors of the mean (SEM). The ANOVA test was used to 
determine statistical significance relative to vehicle treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 
0.05). 
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transfection of the constructs into Ishikawa cells suggested that the response to OHT 
and ICI did not significantly differ and was very similar to that observed in MCF7 
cells (Figure 3.34).  If any differences could be discerned, they also appeared to 
suggest that OHT was a more potent inhibitor in the Ishikawa cells than in the MCF7 
cells. 
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Figure 3.34 - Transient transfection of ER-LBD/AIB-RID split-luciferase constructs into 
Ishikawa cells. 8x103 Ishikawa (A+B) or 12x103 MCF7 (C+D) cells were transfected with 50ng 
Renilla luciferase and 150ng of NLuc-SS-AIB-RID/ER-LBD-SS-CLuc (A+C) or NLuc-ER-LBD/AIB-
RID-SS-CLuc (B+D) in 96 well plates.  Cells were treated with vehicle (ethanol; V) or 10-6M OHT or 
ICI for 48 hours prior to quantification of luciferase activity. Mean firefly luciferase activities (n = 3) 
normalized to Renilla luciferase activities are shown. Error bars represent the standard errors of the 
mean (SEM).  The ANOVA test was used to determine statistical significance (***, p ≤ 0.001, **, p ≤ 
0.01, *, p ≤ 0.05). 
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3.7  SMRT split-luciferase assay 
 
In addition to developing the coactivator based split-luciferase assay to image ERα 
activation, a corepressor assay was also developed to image the interaction between 
the ERα and SMRT.  It was hoped that this would enable active appreciation of ERα 
antagonism by antiestrogens.  
 
In order to develop the assay, the SMRT nuclear receptor interaction domain (SMRT-
RID) was PCR amplified and cloned into the NLuc and CLuc split-luciferase vectors.  
Initially, to determine whether the SMRT-RID constructs were expressed and capable 
of complementation, transfections were performed with the complementary full length 
ERα and truncated ER-LBD constructs (Figure 3.35). 
 
The initial transfection indicated that both of the SMRT-RID constructs were capable 
of complementing with both their reciprocal full length and truncated ERα luciferase 
fusion proteins.  All of the construct pairs produced roughly similar levels of 
luminescence; the brightest construct combination was NLuc-SMRT-RID/ER-LBD-
CLuc, which produced approximately twice the luciferase activity of the least bright 
constructs pairs - the full-length ERα combinations NLuc-SMRT-RID/ER –CLuc and 
NLuc-ER/SMRT-RID-CLuc.    
 
Transfection of NLuc-SMRT-RID with the reciprocal full length and truncated ERα 
constructs produced approximately similar results, which were consistent with our 
expectations; relatively low complementation was observed with vehicle and E2 
treatment and high luciferase activity was observed with the antiestrogens OHT  
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Figure 3.35 - Initial assessment of SMRT-RID constructs. 4x104 293H cells were transfected with 
50ng Renilla luciferase and 150ng of NLuc-SMRT-RID with either ER-LBD-CLuc (A) or ER-CLuc 
(B) or SMRT-RID-CLuc with either NLuc-ER-LBD (C) or NLuc-ER (D). Cells were treated with 
vehicle (ethanol; V) or 10-6M E2 (E), OHT (O) or ICI (I) for 48 hours prior to quantification of 
luciferase activities.  Mean firefly luciferase activities (n = 3) normalized to Renilla luciferase activities 
are shown. Error bars represent the standard errors of the mean (SEM).  The ANOVA test was used to 
determine statistical significance (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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and ICI.  With both the full length and truncated ERα fusion protein, NLuc-SMRT-
RID complementation was slightly greater with OHT treatment versus ICI.  The most 
notable difference between the transfections of NLuc-SMRT-RID with the full length 
and truncated ERα fusion proteins was the complementation observed with E2; with 
full length ERα, only a very slight increase in luciferase activity was observed, 
whereas with the truncated ER-LBD fusion protein the luciferase activity doubled.   
 
Transfection of the reverse orientation fusion proteins, e.g. SMRT-RID fragment 
fused to CLuc and the full length or truncated ERα fragment fused to NLuc, produced 
less consistent results.  Cotransfection of NLuc-ER with SMRT-RID-CLuc produced 
results roughly similar to the NLuc-SMRT-RID/ER-(LBD)-CLuc transfections; 
higher complementation was observed with antiestrogen treatment compared to 
vehicle and E2 treated cells.  However, in NLuc-ER/SMRT-RID-CLuc transfected 
cells, complementation was greatest with ICI rather than OHT treatment and E2 
treatment resulted in a decrease in luciferase activity relative to vehicle.   
 
Contrary to all the other SMRT-RID transfections, however, the NLuc-ER-
LBD/SMRT-RID-CLuc transfected cells produced results inconsistent with our 
understanding of ERα-corepressor interaction; the greatest complementation was 
observed with E2 treatment, OHT treatment produced roughly similar luciferase 
activity and incubation with ICI resulted in intermediate luciferase activity. 
 
In order to ascertain whether the different complementation patterns observed with 
NLuc-ER-LBD/SMRT-RID-CLuc transfected cells were attributable to protein 
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localisation, immunofluorescence was performed on cells treated with E2, OHT and 
ICI (Figure 3.36). 
 
Results from the immunofluorescence broadly agreed with previous experiments 
which had indicated that the full length ERα fusion proteins are predominantly 
nuclear in localisation whereas the truncated ERα fusion proteins are predominantly 
cytoplasmic.  Staining for SMRT indicated that SMRT-RID-CLuc was localized 
within the nucleus and cytoplasm, consistent with its ability to complement with both 
the truncated and full-length ERα fusion proteins.  The NLuc-SMRT-RID fusion 
protein appeared to be predominantly cytoplasmic in localization, which might 
account for the higher overall activity observed when co-transfected ER-LBD-CLuc 
than with ER-CLuc. 
 
No localization patterns were observed which would account for the complementation 
pattern observed in NLuc-ER-LBD/SMRT-RID-CLuc transfected cells; NLuc-ER-
LBD was consistently cytoplasmic and SMRT-RID-CLuc staining was either diffuse 
over the nucleus and cytoplasm, or in the case of ICI treatment, more intensely 
cytoplasmic.   
 
ICI treatment had a similar effect on localization in NLuc-ER/SMRT-RID-CLuc 
transfected cells, where staining for NLuc-ER was more diffuse over the nucleus and 
cytoplasm in ICI treated cells.   
 
In NLuc-SMRT-RID/ER-LBD-CLuc transfected cells, where both constructs were 
predominantly cytoplasmic or had a diffuse distribution, ICI treatment resulted in 
staining for both proteins becoming intensely nuclear in a small proportion of cells.  
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Figure 3.36 - Immunofluorescence of SMRT-RID constructs. 4x104 293 cells were seeded into 
chamber slides prior to transfection with NLuc-SMRT-RID/ER-LBD-CLuc, NLuc-SMRT-RID/ER-
CLuc, NLuc-ER-LBD/SMRT-RID-CLuc or NLuc-ER/SMRT-RID-CLuc.  Cells were treated with 
vehicle (ethanol; V) or 10-6M E2, OHT or ICI for 24 hours prior to staining with mouse-anti-
ERα/Alexa Fluor 594 antibodies and rabbit anti-SMRT/Alexa Fluor 488 antibodies.  Slides were 
mounted with Prolong Gold Antifade with DAPI.  Photographs show ERα (red), SMRT (green) and a 
merged image with DAPI stained nuclei (blue). 
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This effect was only observed in an estimated 20-30% of the cell population, but 
where it did occur, the altered localization appeared to affect both proteins.   
 
Although I still did not entirely appreciate the reasons for the different ligand 
complementation patterns observed with the different fusion protein 
orientations/combinations in the SMRT-RID split-luciferase assay, a more 
comprehensive ligand titration was performed (Figure 3.37).   
 
As previously observed, NLuc-SMRT-RID/ER-LBD-CLuc and NLuc-SMRT-
RID/ER-CLuc showed approximately similar responses to the ligands tested, 
particularly the antiestrogens OHT and ICI.  OHT produced the greatest increase in 
signal, 5- and 6-fold vehicle levels when transfected with ER-LBD-CLuc and ER-
CLuc, respectively.  The increase in signal with OHT incubation was incremental, 
reaching a maximum at 10-6M OHT.  The increased activity observed with ICI was 
slightly less than that observed with OHT with both ER-LBD-CLuc and ER-CLuc;  
incubation with 10-6M ICI produced luciferase activity 4- and 5-fold vehicle levels 
when NLuc-SMRT-RID was transfected with ER-LBD-CLuc and ER-CLuc, 
respectively.  In the presence of increasing quantities of E2, NLuc-SMRT-RID/ER-
LBD-CLuc showed incremental increases in activity reaching a maximum 2-fold 
increase in luciferase activity with 10-7M ligand.  NLuc-SMRT-RID/ER-CLuc also 
showed a similar step-wise increase in activity although the actual increase was only a 
very modest 1.25-fold vehicle activity. 
 
In NLuc-ER/SMRT-RID-CLuc transfected cells the response to the ligands was 
roughly similar to those observed with NLuc-SMRT-RID and ER-CLuc, although the  
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Figure 3.37 - Ligand titration on SMRT-RID constructs. 4x104 293H cells were transfected with 
50ng Renilla luciferase and 150ng of NLuc-SMRT-RID, ER-LBD-CLuc, ER-CLuc, SMRT-RID-CLuc, 
NLuc-ER-LBD and NLuc-ER as indicated. Cells were treated with vehicle (ethanol; V) or increasing 
concentrations of E2, OHT or ICI for 48 hours prior to quantification of luciferase activities.  Mean 
firefly luciferase activities (n = 3) normalized to Renilla luciferase activities are shown. Error bars 
represent the standard errors of the mean (SEM).  The ANOVA test was used to determine statistical 
significance relative to vehicle treatment (***, p ≤ 0.001, **, p ≤ 0.01, *, p ≤ 0.05). 
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potency of the antiestrogens was reversed; a 4-fold increase in signal intensity was 
observed in the presence of 10-6M ICI and 2-fold the vehicle luciferase activity was 
observed with 10-6M OHT.  In the presence of E2, a 30% decrease in signal intensity 
was observed.  Interestingly, the NLuc-ER/SMRT-RID-CLuc transfected cells 
appeared to be more responsive to low concentrations of ligand than the NLuc-
SMRT-RID/ER(-LBD)-CLuc transfected cells, the maximum change in signal in 
response to E2 was observed with 10-9M ligand in the NLuc-ER/SMRT-RID-CLuc 
transfected cells.  Similarly, a greater proportion of the overall increase in signal 
intensity was stimulated by lower levels of the antiestrogens in NLuc-ER/SMRT-
RID-CLuc transfected cells, although the signal continued to increase up to 10-6M 
ligand.  For example, in NLuc-ER/SMRT-RID-CLuc transfected cells approximately 
40% of the total signal increase was observed with 10-10M OHT and 10-9M ICI 
compared to 5% and 15% of the respective signal increase in NLuc-SMRT-RID/ER-
CLuc transfected cells. 
 
Contrary to expectations, but in agreement with the initial transfection, NLuc-ER-
LBD/SMRT-RID-CLuc transfected cells showed the greatest increase in signal with 
E2 and OHT, 3.5- and 3-fold respectively.  In the presence of 10-6M ICI a 2-fold 
increase was observed.  The increases in signal observed with this construct pair were 
all very incremental, reaching a maximum 10-7M or 10-6M ligand. 
 
Results from the ligand titration experiments on the SMRT-RID split-luciferase 
constructs produced mixed and contradictory results, which were difficult to interpret 
without a comparative tool to indicate the endogenous scenario.  Efforts were made to 
establish an immunoprecipitation method to determine how ERα-SMRT interactions 
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alter with ligand treatment, but were not successful in the time allowed.  As such, the 
SMRT split-luciferase assay was not developed any further.  
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Chapter 4 Discussion 
  138
ERα action requires the recruitment of coregulator proteins that facilitate gene 
regulation.  Estrogen promotes coactivator recruitment while antiestrogens can 
promote coactivator and corepressor recruitment in a tissue and ligand selective 
manner.  This suggests that it should be possible to visualize the tissue selective 
action of selective estrogen receptor modulators in vivo by imaging ERα coregulator 
interactions.  The work presented here indicates that a split-luciferase assay can be 
successfully used to image the association of ERα with its coregulators; estrogen 
stimulation of luciferase fragment complementation could be detected in cells 
expressing ERα/AIB1 split-luciferase fusion proteins and increased luciferase activity 
was observed with antiestrogen treatment of cells expressing the SMRT/ER fusion 
proteins.  The experiments conducted show that the split-luciferase assay is suitable 
for imaging ERα-coregulator interactions in vitro and in vivo.  The primed nature of 
the split-luciferase assay enabled changes in protein-protein interaction to be detected 
within 15 minutes of ligand addition and the potential for imaging interaction 
dynamics using this system was demonstrated.   
 
The ERα-AIB1 coactivator interaction assay was developed as a means of assessing 
ERα receptor activation.  ER-LBD and AIB-RID luciferase fusion protein constructs 
with each protein cloned in the N-terminal and C-terminal luciferase configurations 
were produced.  As flexible spacers between fusion protein partners have previously 
been successfully applied, constructs with similar spacer regions were also generated.   
 
In 293 cells transiently transfected with NLuc-SS-AIB-RID/ER-LBD-SS-CLuc and 
NLuc-ER-LBD/AIB-RID-SS-CLuc, E2 stimulated luciferase fragment 
complementation occurred with 10-9M and 10-10M E2 and above, respectively.  For 
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both construct pairs maximum stimulation was observed with 10-6M E2 and 
approximately 50% of maximal activity was observed with 10-9M E2.  This is 
consistent with the dissociation constant (Kd) of E2 bound ERα, which is generally 
reported to be in the range of 10-10 to 10-9M E2 (Anstead et al., 1997).  The 50% 
maximum luciferase fragment complementation observed with 10-9M E2 is also 
broadly consistent with a study of the binding affinity of E2 bound ERα for peptides 
encoding the 3 individual nuclear receptor boxes of AIB1.  This study found the Kd of 
nuclear receptor boxes I and II of AIB1 for E2 bound ERα to be in the region of 2x10-
7M (no interaction was detectable for nuclear receptor box III).  The authors noted 
that the affinity of the native coactivator would likely be greater, due to cooperative 
binding of more than one LXXLL motif  (Bramlett et al., 2001).  The peak ER-AIB1 
interaction observed with 10-6M E2 using the ER-LBD/AIB-RID split-luciferase 
reporters, is also in agreement with yeast two hybrid and GST-pull down assays 
investigating ERα-AIB1 interactions; these studies have reported that maximum 
interaction occurred with E2 concentrations of 10-5M and 10-6M for yeast two hybrid 
and GST-pull down assays, respectively (Kraichely et al., 2000).  
 
The specificity of the observed split-luciferase complementation to E2 induced 
interaction between the ER-LBD and AIB-RID fragments was confirmed by 
antiestrogen modulation of the interaction, mutant ER-LBD constructs and 
cotransfection of ER-LBD/AIB-RID constructs with the reciprocal FRB/FKBP12 
constructs.  Contrary to expectations, cotransfection of NLuc-AIB-RID with 
FKBP12-CLuc resulted in a productive interaction which was modulated by 
rapamycin.  Although this was unexpected, it may represent genuine interaction 
between FKBP12 and AIB1:  FKBP12 is a peptidyl-propyl isomerase (PPI) and other 
  140
members of the PPI family have been shown to interact with the AIB-RID (Siekierka 
et al., 1989, Yi et al., 2005).  Peptidyl-propyl isomerase 1 (Pin1) has been shown to 
interact with amino acids 582-840 of AIB1 (the specific fragment used in this study) 
in a phosphorylation dependent manner to modulate interactions with p300 and 
enhance transcription stimulatory activity (Yi et al., 2005).  Whether this is a genuine 
interaction or an artefact of protein fusion and/or overexpression could be determined 
by cotransfection of NLuc-AIB1-RID with CLuc alone or CLuc fused to another 
example protein such as Myo or Id (Paulmurugan et al., 2002).   
 
The fold change in luciferase activity that was stimulated with E2 incubation of ER-
LBD/AIB-RID transfected cells was consistently less than that observed with 
rapamycin incubation of NLuc-FRB/FKBP12-CLuc transfected cells.  A similar 
situation was also observed for SMRT-RID/ER(-LBD) complementation .  This could 
be partly attributable to the transient nature of ERα-coregulator interactions and the 
lower affinity of interaction between ERα-E2 and AIB1 than that of FKBP12-
rapamycin and FRB: approximately 2x10-7M versus 1.2x10-8M, respectively 
(Metivier et al., 2003, Shang et al., 2000, Bramlett et al., 2001, Banaszynski et al., 
2005).  The greater fold induction observed with the FRB/FKBP12 reporters could 
also be enhanced by the reported absence of interaction between FRB and FKBP12 in 
rapamycin free conditions (Banaszynski et al., 2005).  However, the variability in fold 
induction observed with the different ER-LBD/AIB-RID fusion proteins in different 
orientations and in the presence or absence of spacers, indicates that some of the 
difference in induction observed is attributable to the specific fusion proteins encoded 
by the split-luciferase constructs.  Previous studies have indicated that assisted 
luciferase fragment complementation can be significantly altered with changes in the 
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protein orientation and that inclusion of spacers between fusion protein moieties can 
enhance the function of the fusion partner domains, including their enzymatic activity, 
presumably by reducing interference between fusion partners (Paulmurugan and 
Gambhir, 2007, Galarneau et al., 2002, Newton et al., 1996, Arai et al., 2001).  From 
the present studies, it is unclear whether the altered patterns of luciferase fragment 
complementation observed are attributable to different fusion protein combinations 
improving ER-LBD/AIB-RID fragment interaction or the efficiency of luciferase 
fragment complementation.  Immunoprecipitation experiments might provide further 
insight by directly measuring ER-AIB interaction.  
 
Although in vitro characterisation indicated that E2 stimulated a greater increase in 
luciferase activity with NLuc-ER-LBD/AIB-RID-SS-CLuc than NLuc-SS-AIB-
RID/ER-LBD-SS-CLuc (10- versus 4-fold, respectively), E2 stimulation in vivo 
produced approximately 7-fold increase in luciferase activity with both constructs 
pairs.  In the same experiment, an approximately 20-fold increase in luciferase 
activity was observed in the MELN cell line.  The reason for the increased fold 
induction observed with the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected 293 
and MELN cells could be attributable to a relatively low background signal in the 
placebo treated mice, which might, at least in part, be due a reduced influence of 
estrogen mimics found in tissue culture plastics (Halden, 2010).  This effect would be 
expected to be, and was, most pronounced in the MELN cell line, which is 
particularly sensitive to low concentrations of E2.  A similar increase in fold induction 
in vivo relative to in vitro has been observed with a FRB-FKBP12 split-luciferase 
reporter.  In this case, the authors attributed the changes to improved cell permeability 
in vivo allowing a better delivery of rapamycin (Luker et al., 2004).  Contrary to the 
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other reporters, the NLuc-ER-LBD/AIB-RID-SS-CLuc transfected cells showed a 
reduction in fold induction with E2 treatment in vivo (approximately 7-fold versus 10-
fold in vitro).  However this reporter was also the only one to show reduced activity 
with OHT treatment relative to placebo in vivo, suggesting complementation had been 
stimulated in some manner, possibly prior to implantation.    
 
Although interaction/complementation kinetics were not investigated in vivo, in 
transiently transfected 293 cells, an E2 stimulated increase in luciferase activity could 
be observed with both split-luciferase reporters after 15 minutes of ligand addition.  
With longer E2 incubations, the luciferase signal increased and reached a near 
maximum after 2 hours.  This relatively gradual increase in ER-LBD/AIB-RID 
interaction is in agreement with IP experiments reported in the literature which 
indicate greater interaction between endogenous ERα and AIB1 after 3.5 versus 0.5 
hours E2 incubation (Tikkanen et al., 2000).  Most studies of the kinetics of luciferase 
fragment complementation suggest a plateau in complementation between luciferase 
fragments is reached 10-15 minutes after addition of the interaction inducer, although 
some studies report a maximum being reached within 1-2 minutes (Taneoka et al., 
2009, Luker et al., 2008, Kim et al., 2007a, Yang et al., 2009).  This suggests that the 
time required to reach a signal plateau in the ER-LBD/AIB-RID assay is a reflection 
of the interaction kinetics, not a limitation of the time required for the luciferase 
fragments to complement.  Some studies have reported a requirement of several hours 
to reach a signal maximum, but this has been attributed to the timeframe of changes in 
receptor conformation or the membrane permeability to ligand, not a requirement of 
the luciferase fragments to complement (Luker et al., 2004, Luker et al., 2008).  
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However, it should be noted that none of these studies use the exact luciferase 
fragments used in the present study.   
 
The ability to image interaction dynamics was investigated by addition of the 
competitive inhibitor OHT to E2 stimulated cells; in 293 cells transiently transfected 
with the ER-LBD/AIB-RID split-luciferase constructs, a reduction in luciferase 
activity was observed within 15 minutes of OHT addition.  Although inconsistencies 
were noted in the “minute” and “hour” time-course studies of signal ablation, 
depending on the specific construct pair, full ablation of the E2 induced signal was 
observed after 4-8 hours OHT incubation.  The reduced induction observed with E2 
and slower decline in signal observed with OHT in the minute time-course studies is 
most likely a consequence of sub-optimal culture conditions, brought about by 
removal of the plates from the incubator for ligand addition every 15 minutes.  In 
contrast to fluorescent protein complementation assays, which are generally regarded 
to be irreversible, luciferase fragment complementation assays are thought to be more 
reversible; if the interacting proteins of interest cease to interact then the luciferase 
fragments will dissociate and cease to complement (Hu et al., 2002, Magliery et al., 
2005, Nyfeler et al., 2005).  Split-luciferase assays using Renilla, Gaussia and click 
beetle luciferases have all been argued to be reversible, although only one report uses 
an inhibitor of protein translation to fundamentally determine that the loss of 
luciferase activity observed is independent of protein turnover (Villalobos et al., 2010, 
Remy and Michnick, 2006, Stefan et al., 2007).  In general, these kinetics studies have 
shown that a reversal of luciferase fragment complementation occurs within 10-30 
minutes.  However, a study of the association of the androgen receptor with a 
coactivator LXXLL motif, which claims the interaction of the click beetle fragments 
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is reversible (although no translation inhibitor is used), indicates that full signal 
ablation is not observed until 2 hours after ligand removal (Kim et al., 2007b).  This is 
a very similar timeframe to that observed in the present study for the dissociation of 
the ER-LBD and AIB-RID LXXLL-based interaction, and could suggest that the 
change in signal observed with OHT addition is reflective of ER-AIB interaction, not 
a limitation of luciferase fragment dissociation or protein turn-over.  The different 
timeframes required for signal ablation in NLuc-ER-LBD/AIB-RID-SS-CLuc and 
NLuc-SS-AIB-RID/ER-LBD-SS-CLuc transfected cells could be a reflection of the 
specific protein moieties hindering ER-LBD/AIB-RID dissociation in the NLuc-SS-
AIB-RID/ER-LBD-SS-CLuc cells; in both transiently transfected 293 cells and in 
U2OS stable cell lines, the NLuc-SS-AIB-RID/ER-LBD-SS-CLuc luciferase signal 
took longer to ablate than the NLuc-ER-LBD/AIB-RIB-SS-CLuc signal.  However, 
from the experiments performed, one cannot exclude the possibility that this is a 
reflection of the stability of the different fusion proteins.  It is possible that the firefly 
luciferase fragments in the ER-LBD/AIB-RID complementation assay do irreversibly 
lock together and that OHT treatment reduces the luciferase activity by blocking the 
association of newly translated fusion proteins.   
 
Regardless of the mechanism through which changes in the ligand environment are 
transposed to an alteration in the luciferase signal, the ability to image changes in 
protein-protein interactions in a timely fashion is advantageous and could be of great 
use for in vitro screening as well as in vivo evaluation of the pharmacodynamics of 
novel ERα targeted therapies.  
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Experiments conducted to date indicate that the ER-LBD/AIB-RID split-luciferase 
reporters can be used to image the action of antiestrogens in vivo.  Administration of 
the breast cancer drug Faslodex (ICI) to nude mice was able to reduce the increased 
complementation observed with E2.  The degree of signal ablation observed differed 
between the two reporters, which may be an artefact or may represent subtle 
differences in the reporter responses in vivo.  The differences in signal ablation cannot 
be attributed to variability in the Faslodex doses administered because each mouse 
gave a measure for both reporters.  Most unexpectedly, administration of Faslodex 
alone (with placebo rather than E2 pellet) stimulated a high level of luciferase 
fragment complementation.  Although there was considerable variability in the 
individual measurements, this effect was observed with both reporters and so cannot 
be attributed to irregular cell implantation.  ICI is generally regarded as a “pure” 
antiestrogen: it exerts no ERα agonist properties.  This had been thought to be a result 
of disrupting nucleocytoplasmic shuttling and increasing turnover of ERα but recent 
evidence suggests it could be a consequence of the receptor conformation ICI induces 
(Dauvois et al., 1992, Dauvois et al., 1993, Howell et al., 2000, Wardell et al., 2011).  
However, in tissues other than breast and endometrium, particularly neurons and 
bone, there is evidence that ICI exhibits a degree of ER agonist activity, particularly at 
lower clinically relevant levels (Sibonga et al., 1998, Zhao et al., 2006).  As such, it is 
possible that the split-luciferase activity observed in the Faslodex treated mice is a 
result of this agonist type activity.  However, further investigation would be required 
to determine whether this effect could be observed in vitro and whether it is detected 
using the split-luciferase reporters in an MCF7 background or in the MELN cell line.  
It is feasible that this could be a temporary effect which would subside with later 
imaging time points: this could be better investigated better with the stable cell lines.    
  146
 
Using the antiestrogen OHT, I was unable to attenuate the E2 induced signal of the 
split-luciferase constructs in vivo, although a moderate reduction of the E2 induced 
signal in the MELN cell line was achieved.  The modest reduction observed with the 
MELN cell line suggests that the concentration of OHT achieved was relatively low.  
Previous studies have indicated that achieving clinically relevant levels of tamoxifen 
and its major metabolites in nude mice is challenging because metabolism of the drug 
is different to that in rat and man (Robinson et al., 1991, DeGregorio et al., 1989, 
DeGregorio et al., 1987, Kisanga et al., 2003).  In circumstances such as this, the ER-
SMRT split-luciferase reporter could be particularly useful.  Use of the corepressor 
assay would enable direct appreciation of ERα antagonism, without a reliance on 
inhibition of an E2 induced signal.   
 
In order to study the interaction of ER with the corepressor SMRT, NLuc and CLuc 
SMRT-RID fusion proteins were produced and transfected with both full length ERα 
and truncated ER-LBD constructs.  Transfection of NLuc-SMRT-RID with either ER-
CLuc or ER-LBD-CLuc, and NLuc-ER with SMRT-RID-CLuc produced broadly 
similar results, which were consistent with the role of SMRT as an ERα corepressor.  
Increased luciferase fragment complementation was observed with the antiestrogens 
OHT and ICI and minimal changes were observed with E2.  However, between the 
different construct pairs there were inconsistencies regarding the action of E2 and 
which antiestrogen produced the greatest luciferase fragment complementation.  
Whether these difference complementation patterns are a reflection of different ER(-
LBD)/SMRT-RID fusion protein interaction or a reflection of the ability of the 
luciferase fragments to complement within different protein environments would 
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require further investigation.  IP experiments would also be required to determine 
which construct pair most faithfully reflects the interaction of ERα and SMRT before 
proceeding with the ER-corepressor assay.  
 
In contrast to the broadly consistent results obtained with the other ER(-LBD)/SMRT-
RID constructs, cotransfection of NLuc-ER-LBD with SMRT-RID-CLuc produced 
the greatest luciferase fragment complementation in the presence of E2 and OHT, but 
relatively low complementation with ICI.  The similar complementation observed 
with E2 and OHT is very surprising since the ligands are known to produce distinct 
receptor conformations which promote or occlude ERα-SMRT interaction (Shiau et 
al., 1998, Shang and Brown, 2002, Webb et al., 2003).  Interestingly, Paulmurugan 
and Gambhir report similar “ligand pharmacology independent” complementation in a 
Renilla luciferase ER-LBD intramolecular folding sensor.  Using this reporter, 
removal of the ERα F domain (amino acids 549-595) enabled E2 and OHT to be 
distinguished (Paulmurugan and Gambhir, 2006).  Whether removing the F domain 
from NLuc-ER-LBD would enable differential complementation in response to E2 
and OHT when co-transfected with SMRT-RID-CLuc remains unclear.  Regardless, 
the ligand induced complementation pattern observed with NLuc-ER-LBD and 
SMRT-RID-CLuc suggest they would not make a good ER-SMRT interaction 
reporter.    
 
One of the principal aims in developing the ERα split-luciferase assay was to 
determine whether the method could be employed to visualise the tissue selective 
actions of ERα ligands.  To this end, the ER-LBD/AIB-RID constructs were stably 
transformed into MCF7 breast cancer and U2OS osteosarcoma cell lines. A 
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comparison of the E2 response in the U2OS and MCF7 cells lines indicated that tissue 
selective patterns of luciferase fragment complementation could be detected.  In 
U2OS cell lines stably expressing NLuc-ER-LBD and AIB-RID-SS-CLuc, the 
kinetics and fold induction of E2 stimulated luciferase activity was consistently more 
rapid and of greater magnitude than in MCF7 cells expressing the same fusion 
proteins.  Similarly, the signal ablation observed with OHT addition to E2 stimulated 
cells was also much more rapid in the U2OS compared to MCF7 stable cell lines.  
Although the influence of fusion protein stability on these patterns of 
complementation would need to be confirmed, the results obtained indicate that the 
split-luciferase assay is sensitive to the specific cellular context and therefore offers 
the potential to image tissue specific interactions between ERα and AIB1.  The tissue 
specific complementation patterns observed with the ER-LBD/AIB-RID split-
luciferase reporters in U2OS and MCF7 cells is supported by previous ChIP and 
ERE-luciferase transgenic mice studies which have shown that the transcriptional 
response to E2 is cell type specific and that different tissues show a different time-
course and amplitude of signal in response to E2 (Della Torre et al., 2011, Rando et 
al., 2010, Frasor et al., 2003, Krum et al., 2008).   
 
Though some tissue specific patterns of complementation could be observed with the 
ER-LBD/AIB-RID split-luciferase constructs, I was unable to detect the agonist 
actions of OHT in bone or endometrial cell lines.  OHT produced a similar ERα 
antagonist response in the ER-LBD/AIB-RID split-luciferase reporters in breast, bone 
and endometrial cell lines, which made it indistinguishable from the pure antiestrogen 
ICI.  This is perhaps somewhat unsurprising given that the antagonist actions of OHT 
have been attributed to the N terminal AF1 region, which is absent from the ER-LBD 
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fusion proteins (Berry et al., 1990).  In order to most accurately reflect endogenous 
ERα-AIB1 interaction, luciferase fusion proteins with full-length ERα and AIB1 
would be required.  Full length proteins would be receptive to the alterations in cell 
signalling and protein-protein interactions which regulate the interaction of ERα and 
AIB1.  During the course of the project, extensive efforts were made to produce full 
length ERα and AIB1 fusion proteins.  After initial cloning difficulties, NLuc and 
CLuc full length fusion proteins were produced and transient transfection of 
constructs indicated that E2 stimulated an increase in luciferase activity.  However, 
because the luminescent signal was very low, stable cell line generation was initiated 
prior to characterization.  Unfortunately, time constraints prevented completion of the 
work to generate such lines and therefore it was not possible to determine the impact 
of full length proteins on the split-luciferase assay.    
 
4.1  Conclusions and Future Directions 
Luciferase imaging is a powerful tool for non-invasive preclinical imaging.  It offers 
the potential for relatively cheap, sensitive and high throughput imaging of tumour 
biology in modified cells or organisms.  The present study has shown that using ER-
LBD, AIB-RID and SMRT-RID luciferase fragment fusion proteins, the interaction of 
ERα with its coactivator and corepressor can be imaged.  Although the assay requires 
further validation, the split-luciferase method offers distinct advantages over 
previously used fluorescence based techniques for imaging ERα-coregulator 
interaction: namely, that the luciferase method can be applied to in vivo imaging of 
protein-protein interactions.  This would allow the modulation of interactions in a 
native tumour environment to be appreciated.  Previous in vivo studies of ERα activity 
have focused on transcriptional reporters, which although undoubtedly a valuable 
  150
technique, are limited in their potential to image the dynamics of ERα activation 
because of the lag associated with signal accumulation and ablation.  Furthermore, 
imaging ERα-coregulator interactions, which are assumed to be common to all E2 
regulated genes and are a prerequisite for transcription of estrogen-regulated genes, 
could be considered broader and more indicative of the global ERα signalling than 
transcriptional reporters, which focus on the activity of ERα and ERβ at a select 
number of promoters or genes.  
 
In the stable cell line format, the present assay offers a fast, easy and potentially high 
throughput method for assessing alterations in E2 induced ER-AIB1 interaction and 
could be applied to the screening of novel compounds.  The assay could be 
particularly useful for novel compounds which aim to block the ERα-LXXLL 
interaction, rather than targeting the ligand binding pocket (Galande et al., 2005, 
Geistlinger et al., 2004, Gunther et al., 2008, Rodriguez et al., 2004).  Although less 
developed, the ER-LBD-SMRT-RID offers similar potential for screening novel 
antiestrogens which induce a conformation that promotes corepressor binding.  The 
capacity to screen compounds in an appropriate cellular background offers advantages 
over other high throughput cell free systems.  And the ability to transfer the split-
luciferase method from a high throughput screening tool to an in vivo method for 
studying the pharmacodynamics of newly identified compounds is also beneficial.   
 
Using the current ER-LBD/AIB-RID assay, the potential for imaging tissue specific 
ERα-AIB1 interactions was alluded to.  However, in order to maximise the sensitivity 
of the assay to the detection of tissue specific endogenous interactions, the assay 
would be best performed using full-length receptor/coregulator fusion proteins.  Using 
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such proteins, the impact of post-translational modification, interactions with other 
proteins and native protein regulation, could be appreciated on the interaction of ERα 
with its coregulators.  Similar to the ERE-luciferase mice, transgenic mice expressing 
the full length ERα/coregulator fusion proteins could be generated to visualise the 
impact of E2 signalling in different tissues at different stages of the estrus cycle and in 
response to different ER ligands.  However, because of the potential transformative 
effects of over-expressing ERα and AIB1, transgenic knock-in mice would need to be 
established.  This would ensure appropriate expression levels of both proteins in 
tissues and would ensure that overexpression of the proteins was not altering the 
native signalling in different cell types.  However, with a native expression system 
difficulties could be encountered in imaging ERα-AIB1 interaction in tissues with 
relatively low expression levels or in deep tissues.  In order to overcome this, the 
luciferase fragments could be changed to split thymidine kinase fragments, to enable 
PET imaging of protein-protein interactions or to a genetically encoded BRET system 
for optical imaging (Dragulescu-Andrasi et al., 2011, Massoud et al., 2010).  
Switching to a PET system would enable very sensitive, highly resolved, 3D, deep 
tissue imaging.  However, a potential hindrance for the split-luciferase assay is the 
idiosyncratic nature of assisted complementation between luciferase fragment fusion 
proteins; it is difficult to know whether results are specific to the interaction between 
the proteins of interest or related to the ability of the luciferase fragments to 
complement in a given protein environment or receptor conformation.  Changing to a 
BRET based system could overcome this issue because a BRET signal is produced 
through the transfer of energy, which is subject to less interference from the protein 
environment than the complementary folding of protein fragments.  A recent study 
reported successful deep tissue imaging of protein-protein interactions using a novel 
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BRET system with an emission spectrum of 640nm (Dragulescu-Andrasi et al., 2011).  
The immediate nature of energy transfer in the BRET system could also improve the 
potential for imaging interaction kinetics.   
 
In the future, the current split-luciferase based assay could also be developed to image 
the interaction of ER-LBD with AIB-RID and SMRT-RID in the same cell by using 
red and green click beetle luciferases, as recently demonstrated (Villalobos et al., 
2010).  Additionally, the assay could be expanded to investigate the differences 
between ligand induced ERα and ERβ coregulator recruitment.  It has been suggested 
that some of the tissue specific actions of certain ligands could be attributable to 
differential activity with ERα and ERβ and there is some interest in developing ERβ 
specific agonists (Gustafsson, 2003, Meyers et al., 2001).  Alternatively, the 
interaction of ERα and ERβ with a single coregulator could be investigated using the 
dual colour click beetle system, although the ability of ERα and ERβ to 
heterodimerise might complicate this (Pace et al., 1997).   
 
Nuclear receptors have been shown to be involved in a number of different human 
diseases and their ligand dependent transcriptional regulation have made them 
attractive targets for drug development (Sladek, 2003).  The interaction of nuclear 
receptors with coregulators, and the meaning this has for receptor activity, also makes 
nuclear receptor-coregulator interactions highly applicable to luciferase fragment 
complementation assays as a means of gauging receptor activity.  As such, the 
approach detailed in this report could be applied to a number of different nuclear 
receptor-coregulator protein pairs with the aim of screening novel compounds in vitro 
and confirming and further characterising identified compounds in vivo.  
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